Patent Publication Number: US-2022233576-A1

Title: Solute carrier family 46 member 3 (slc46a3) as marker for lipid-based nanoparticle cancer therapy and diagnostics

Description:
CROSS REFERENCE 
     This application claims priority to U.S. Provisional Patent Application Serial Nos. 63/140,315 filed Jan. 22, 2021; 63/170,874 filed Apr. 5, 2021; and 63/248,438 filed Sep. 25, 2021; each incorporated by reference herein in its entirety. 
    
    
     FEDERAL FUNDING STATEMENT 
     This invention was made with Government support under Grant No. W81XWH-19-1-0257 awarded by the United States Army Medical Research Acquisition Activity and Grant No. T32 CA126432-08 awarded by the National Institutes of Health. The Government has certain rights in the invention. 
    
    
     SEQUENCE LISTING STATEMENT 
     A computer readable form of the Sequence Listing is filed with this application by electronic submission and is incorporated into this application by reference in its entirety. The Sequence Listing is contained in the file created on Jan. 20, 2022 having the file name “21-1488-US-SeqList_ST25.txt” and is 31 kb in size. 
     BACKGROUND 
     Cancer nanomedicine has attracted intense research and clinical interest given the potential to tune nanomaterials for enhanced drug delivery sites of disease. Nanoparticles have been established to improve therapeutic properties largely by extending circulation time and mitigating toxic side effects. Targeting strategies have been devised in an effort to improve the specificity of nanoparticle-cancer cell interactions, but tumor accumulation remains below 1% of the injected dose. Progress has been impeded by a limited understanding of the cellular processes governing these interactions in cancer cells of heterogeneous lineage and genetic backgrounds. 
     SUMMARY 
     In a first aspect, the disclosure provides methods of identifying a subject who is susceptible to treatment for cancer with lipid-based nanoparticle therapies, the method comprising determining expression levels of solute carrier family 46 member 3 (SLC46A3) in a plurality of cancer cells from a subject having cancer, wherein a subject with decreased SLC46A3 expression levels as compared to historical controls is susceptible to treatment with lipid-based nanoparticles. 
     In one embodiment, the disclosure provides methods of identifying cancer cells susceptible to treatment with lipid-based nanoparticle therapies, the method comprising 
     (a) obtaining cancer cells from a subject; and 
     (b) determining expression levels of SLC46A3 in said cells, wherein the cells with decreased SLC46A3 expression levels as compared to historical controls are susceptible to treatment with lipid-based nanoparticles. 
     In one embodiment, the method further comprises administering to a subject identified as susceptible to treatment with lipid-based nanoparticle therapies or identified as having cancer cells susceptible to treatment with nanoparticles, an amount effective to treat or diagnose cancer of a lipid-based cancer therapy nanoparticle. In a further embodiment, the methods further comprise monitoring the lipid-based cancer therapy nanoparticle treatment in the subject, comprising determining expression levels at multiple time points of SLC46A3 in a plurality of cancer cells from a subject, wherein the expression levels at later time points relative to the expression level at earlier time points indicates an efficacy of the lipid-based cancer therapy nanoparticle in the subject. 
     In another aspect, the disclosure provides methods of treating cancer in a subject, the method comprising 
     (a) identifying a subject with cancer cells, such as malignant cells, that have a normal or increased SLC46A3 expression level as compared to historical controls, and 
     (b) delivering to said subject an amount effective to treat the cancer of:
         (i) a composition to decrease SLC46A3 expression; and   (ii) a lipid-based cancer therapy nanoparticle.       

     In one embodiment, the lipid-based nanoparticle comprises a liposomal nanoparticle. In another embodiment, the lipid-based nanoparticle comprises a solid lipid nanoparticle. 
     In another aspect, the disclosure provides compositions for treating cancer, the composition comprising 
     (a) an inhibitor of SLC46A3 expression; and 
     (b) a lipid-based chemotherapeutic-containing nanoparticle. 
     In one aspect, the disclosure provides methods of identifying subjects suitable for enrollment in a clinical trial for nanoparticle cancer therapy, comprising the following steps: 
     a) determining expression levels of SLC46A3 in a plurality of cells from multiple subjects diagnosed with cancer; 
     b) further determining whether the SLC46A3 expression levels from said patients are increased or decreased levels of expression as compared to historical controls, and 
     c) identifying as subjects suitable for enrollment in a clinical trial for nanoparticle cancer therapy those patients with decreased SLC46A3 expression levels compared to historical controls. 
    
    
     
       DESCRIPTION OF THE FIGURES 
         FIG. 1 . Native expression of the lysosomal transporter SLC46A3 is strongly predictive of NP-cell interaction for liposome formulations. (A) Univariate analysis identifies SLC46A3 expression as strongly yet inversely correlated with liposome association, regardless of liposomal surface modification. (B) Using linear regression to evaluate the biomarker relationship across core formulations reveals SLC46A3 expression is inversely correlated with NP association in liposome-cell line pairs (p&lt;0.001) but not PLGA- and PS-cell line pairs (p&gt;0.05); n=488 for each plot. (C) Cell lines in the pool exhibit a range of natural SLC46A3 expression levels with a log linear correlation with uptake of liposomes. (D) This correlation is also exhibited when assessing liposome-cell associations via flow cytometry in a non-pooled fashion (p=0.013). Cell lines in red were not part of the pooled screen. Data represented in D is shown as the mean and standard deviation of four biological replicates. 
         FIG. 2 . Modulating SLC46A3 expression in cancer cell lines is sufficient to negatively regulate interaction with liposome NP formulations. (A) T47D and LOXIMVI cells have high and low SLC46A3 expression, respectively, with respect to SLC46A3 expression levels represented in the cell line pool. (B) LOXIMVI cells have predominantly high association with all tested liposomal NP formulations and T47D cells have low association with all tested liposomal NP formulations. (C) Representative micrographs of signal in engineered cell lines showing endolysosomal compartments. Scale bars=10 μm. (D) Using lentivirus to overexpress SLC46A3 in LOXIMVI cells and CRISPR/Cas9 to knock out SLC46A3 in T47D cells, we show that modulation results in significantly changed liposome association, as determined via flow cytometry (** p&lt;0.001, Kruskal-Wallis test), NP-associated fluorescence is defined as median fluorescence intensity normalized to untreated cells. Data is represented as the mean and standard deviation of four biological replicates. (E) These shifts in NP association were consistently observed across all tested liposomes, independent of surface modification. No shifts were observed with PLGA or PS formulations. 
         FIG. 3 . High throughput imaging cytometry confirms NP internalization and reveals SLC46A3 dependent changes to intracellular trafficking. (A) Imaging cytometry was used to investigate the intensity (x-axis) and distribution (y-axis) of NPs in a high-throughput manner. Bivariate density plot of n=10,000 cells (T47D-vector control) after 24 h incubation with LIPO-PLD NPs, with representative cell images at low and high NP signal. (B) Cellular distribution patterns of NPs were scored such that scores greater than 0 indicate cells with internalized NPs. Representative data from LIPO-PLD NPs in engineered T47D cells are shown. (C) Representative cell images at the median cellular distribution score for engineered T47D cells treated with LIPO-PLD NPs. (D) Quantification of median intensity of tested NP formulations in engineered T47D and LOXIMVI cell lines demonstrated SLC46A3-dependent changes. (E) NPs remained predominantly internalized independent of SLC46A3 expression levels. (F) Shifts in the median cellular distribution scores were observed in response to SLC46A3 modulation. Live cell micrographs of (G) T47D-vector control and T47D-SLC46A3 knockout cells and (H) LOXIMVI-vector control and LOXIMVI-SLC46A3 OE cells incubated with LIPO-PLD and PLGA-PLD NPs for 24 h. Scale bar=5 μm. 
         FIG. 4 . Retention and accumulation of PEGylated liposomes (LIPO-0.3% PEG*) in LOXIMVI tumors is dependent on SLC46A3 expression. (A) Fluorescently labeled LIPO-0.3% PEG* NP were administered to mice bearing LOXIMVI flank tumors via a one-time intratumoral injection or repeat intravenous injections. (B) Whole animal fluorescence images of mice (4 males, 6 females per group) 24 h after being intratumorally injected with LIPO-0.3% PEG* NPs. (C) Quantification of LIPO-0.3% PEG* NP retention after intratumoral administration to LOXIMVI flank tumors. (D) Quantification of LIPO-0.3% PEG* NP accumulation after repeat IV injections. In panels C-D, nanoparticle signal is expressed on the y-axis as radiant efficiency divided by tumor mass (mg). The mean and standard deviation of n=10 are shown with the exception of the LOXIMVI-vector control, repeat IV injection group, where n=9 (**&lt;0.01, ***&lt;0.001, Mann-Whitney test). 
         FIG. 5  Expanded SLC46A3 univariate analysis and lineage analysis. (A) Gene expression of SLC46A3 was a significant biomarker with negative z-score for liposome (LIPO) formulations with and without PEG and more significant at 24 h than at 4 h. Volcano plots for six liposomal NP formulations highlighting the position of SLC46A3 biomarker, which has higher significance and more negative z-score at 24 h compared to 4 h. SLC46A3 expression was not a top hit for (B) PLGA or (C) PS formulations at either time point. (D) The inverse relationship of SLC46A3 expression was observed for tested LIPO formulations regardless of cancer cell lineage. 
         FIG. 6 . Expanded non-pooled screening via flow cytometry of cell interactions with (A) liposomal and (B) PS NP formulation at 24 h. Data is represented as the mean and standard deviation of four biological replicates. 
         FIG. 7 . Flow cytometry profiling of engineered cell lines after SLC46A3 modulation. After transduction (lentiviral dose, 0-400 μL), LOXIMVI were cultured (A, C) with and (B, D) without blasticidin (blast). Cells were then incubated with liposomal NPs (bare LIPO) for 24 h prior to flow cytometry analysis with NP-associated fluorescence detected in the APC-A channel. (A, B) A virus concentration-dependent decrease in liposome-cell association is observed but not in (C, D) the vector control cells. (E) Summary of qPCR profiling of SLC46A3 in LOXIMVI cells. (F) Ribosomal RNA count of cell samples used to generate PCR data in panel E. (G) Quantification of liposomal association with clonal T47D-SLC46A3 knockouts generated using the CRISPR/Cas9 system. Three clonal populations were tested for the SLC46A3 knockout to ensure a consistent phenotype was observed. Data is represented as the mean and standard deviation of six biological replicates. (H) Representative flow histograms of clonal populations treated with liposomal NPs for 24 h; with NP-associated fluorescence detected in the APC-A channel. (I) Flow cytometry analysis reveals SLC46A3-related trends in liposomal NP association with T47D cells are maintained with and without serum present in cell culture medium. T47D cells were cultured either with or without 10% FBS and treated with liposomal NPs for 24 h. Flow cytometry was used to quantify the liposome-cell association extent, and median fluorescence intensity (MFI) values for the vector control and SLC46A3 KO cells were divided by the MFI of the liposome-treated parental T47D cells. Significant increases in liposome association (*, p&lt;0.05, Mann-Whitney) were observed in SLC46A3 KO in both groups. Data is represented as the mean and standard deviation of four biological replicates. 
         FIG. 8 . Liposomal nanoparticles exhibit SLC46A3-dependent changes in intracellular trafficking. Live cell micrographs of (A) LIPO-PLE and LIPO-0.3% PEG* NPs incubated with engineered T47D and LOXIMVI cells for 24 h. (C) Live cell micrographs of LIPO-PLD NPs incubated with T47D and LOXIMVI cells for 4 h. Scale bar=5 μm. 
         FIG. 9 . Raw data and histology images for in vivo studies. (A) Flow cytometry histograms for LIPO-0.3% PEG* (drug-free analog of liposomal irinotecan) in LOXIMVI cells overexpressing SLC46A3 (SLC46A3 OE) or luciferase (vector control) after 4 and 24 hours incubation wth NPs. (B) In vivo fluorescence images of mice bearing LOXIMVI flank tumors (n=10/group, 5 male and 5 female) 4 hours after intratumoral injection with LIPO-0.3% PEG* NPs. (C) Radiant efficiency from ex vivo tumors quantified in (D). Radiant efficiency from ex vivo tumors used to generate plots in main manuscript  FIG. 4C  (E) and  FIG. 4D  (F). (G) H&amp;E staining of LOXIMVI tumor cross-sections show grossly similar morphology. Top two panels, scale bar=2 mm; bottom two panels, scale bar=0.1 mm. 
     
    
    
     DETAILED DESCRIPTION 
     As used herein and unless otherwise indicated, the terms “a” and “an” are taken to mean “one”, “at least one” or “one or more”. Unless otherwise required by context, singular terms used herein shall include pluralities and plural terms shall include the singular. 
     Unless the context clearly requires otherwise, throughout the description and the claims, the words ‘comprise’, ‘comprising’, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of “including, but not limited to”. Words using the singular or plural number also include the plural or singular number, respectively. Additionally, the words “herein,” “above” and “below” and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of this application. 
     All embodiments of any aspect of the invention can be used in combination, unless the context clearly dictates otherwise. 
     As used herein, “about” means+/−5% of the recited value. 
     In a first aspect, the disclosure provides methods of identifying a subject who is susceptible to treatment for cancer with lipid-based nanoparticle therapies, the method comprising determining expression levels of solute carrier family 46 member 3 (SLC46A3) in a plurality of cells from a subject having cancer, wherein a subject with decreased SLC46A3 expression levels as compared to historical controls is susceptible to treatment with lipid-based nanoparticles. 
     In one embodiment, the disclosure provides methods of identifying cancer cells susceptible to treatment with lipid-based nanoparticle therapies, the method comprising 
     (a) obtaining cancer cells from a subject; and 
     (b) determining expression levels of SLC46A3 in said cells, wherein the cells with decreased SLC46A3 expression levels as compared to historical controls are susceptible to treatment with lipid-based nanoparticles. 
     As disclosed in the attached examples, the inventors have identified SLC46A3 as a biomarker whose expression inversely predicts lipid-based nanoparticle uptake both in vitro and in vivo, and have identified SLC46A3 expression reduction as a means to improve lipid-based nanoparticle delivery to cancers, and thus to improve cancer therapies. 
     The human SLC46A3 gene sequence is provided as SEQ ID NO:1, and the protein sequence is provided as SEQ ID NO:2 (NCBI Reference Sequence: NC_000013.11). 
     As used herein, a “nanoparticle” is any particle with a widest diameter in the nm scale (1-999 nm). 
     As used herein, a “lipid-based nanoparticle” is any nanoparticle comprised of lipids, including but not limited to liposomal nanoparticles and solid lipid nanoparticles. 
     As used herein, “nanoparticle therapies” comprise nanoparticle delivery of cancer therapeutics or diagnostics to a subject. In one embodiment, the nanoparticle comprises nanoparticle delivery of cancer therapeutics to a subject. 
     As used herein, “nanoparticle delivery” is defined as the accumulation of nanoparticles containing diagnostic and/or therapeutic modalities in cancer cells. 
     Any suitable lipid-based nanoparticle therapy may be implicated in the methods disclosed herein, as deemed appropriate by attending medical personnel. In various non limiting embodiments, the lipid-based nanoparticle therapy is selected from the group consisting of cancer therapy nanoparticles shown in Table 1. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Exemplary clinically approved nanoparticle therapies and diagnostics, grouped by their broad indication 
               
            
           
           
               
               
               
               
            
               
                   
                   
                 Approved 
                 Investigated 
               
               
                 Name 
                 Particle type/drug 
                 application/indication 
                 application/indication 
               
               
                   
               
               
                 VYXEOS 
                 Liposomal formulation of 
                 Acute myeloid leukemia 
                 Various leukemias 
               
               
                 CPX-351 
                 cytarabine:daunorubicin 
               
               
                 (Jazz 
                 (5:1M ratio) 
               
               
                 Pharmaceuticals) 
               
               
                 NBTXR3 
                 Hafnium oxide nanoparticles 
                 Locally advanced 
                 Locally advanced soft tissue 
               
               
                 Hensify 
                 stimulated with external 
                 squamous cell carcinoma 
                 sarcoma 
               
               
                 (Nanobiotix) 
                 radiation to enhance tumor 
               
               
                   
                 cell death via electron 
               
               
                   
                 production 
               
               
                 Doxil 
                 Liposomal doxorubicin 
                 Ovarian cancer 
                 Various cancers including: 
               
               
                 Caelyx 
                 (PEGylated) 
                 (secondary to platinum 
                 solid malignancies, ovarian, 
               
               
                 (Janssen) 
                   
                 based therapies) 
                 breast, leukemia, 
               
               
                   
                   
                 HIV-associated Kaposi&#39;s 
                 lymphomas, prostate, 
               
               
                   
                   
                 sarcoma (secondary to 
                 metastatic, or liver 
               
               
                   
                   
                 chemotherapy) 
               
               
                   
                   
                 Multiple myeloma 
               
               
                   
                   
                 (secondary) 
               
               
                 DaunoXome 
                 Liposomal daunorubicin 
                 HIV-associated Kaposi&#39;s 
                 Various leukemias 
               
               
                 (Galen) 
                 (non-PEGylated) 
                 sarcoma (primary) 
               
               
                 Myocet 
                 Liposomal doxorubicin 
                 Treatment of metastatic 
                 Various cancers including: 
               
               
                 (Teva UK) 
                 (non-PEGylated) 
                 breast cancer (primary) 
                 breast, lymphoma, or ovarian 
               
               
                 Abraxane 
                 Albumin-particle bound 
                 Advanced non-small cell 
                 Various cancers including: 
               
               
                 (Celgene) 
                 paclitaxel 
                 lung cancer (surgery or 
                 solid malignancies, breast, 
               
               
                   
                   
                 radiation is not an option) 
                 lymphomas, bladder, lung, 
               
               
                   
                   
                 Metastatic breast cancer 
                 pancreatic, head and neck, 
               
               
                   
                   
                 (secondary) 
                 prostate, melanoma, or liver 
               
               
                   
                   
                 Metastatic pancreatic 
               
               
                   
                   
                 cancer (primary) 
               
               
                 Marqibo 
                 Liposomal vincristine 
                 Philadelphia 
                 Various cancers including: 
               
               
                 (Spectrum) 
                 (non-PEGylated) 
                 chromosome-negative 
                 lymphoma, brain, leukemia, 
               
               
                   
                   
                 acute lymphoblastic 
                 or melanoma 
               
               
                   
                   
                 leukemia (tertiary) 
               
               
                 MEPACT 
                 Liposomal mifamurtide 
                 Treatment for 
                 Osteosarcomas 
               
               
                 (Millennium) 
                 (non-PEGylated) 
                 osteosarcoma (primary 
               
               
                   
                   
                 following surgery) 
               
               
                 Onivyde 
                 Liposomal irinotecan 
                 Metastatic pancreatic 
                 Various cancers including: 
               
               
                 MM-398 
                 (PEGylated) 
                 cancer (secondary) 
                 solid malignancies, breast, 
               
               
                 (Merrimack) 
                   
                   
                 pancreatic, sarcomas, or 
               
               
                   
                   
                   
                 brain 
               
               
                   
               
            
           
         
       
     
     As used herein, “expression levels” of SLC46A3 may comprise protein expression levels, RNA expression levels, or both. In one embodiment, the expression level comprises gene expression levels of RNA. 
     The plurality of cells from the subject may be any cancer cells obtained from the subject. In various embodiments, the plurality of cells may comprise cells obtained from any suitable biological sample from the subject, including but not limited to cancer cells obtained via biopsy or cancer-directed surgery or via blood sample, cerebrospinal fluid sample, urine sample, peritoneal fluid sample, pleural fluid sample, or any other bodily fluid sample containing cancer cells. 
     As used herein, “historical controls” may be any suitable control for comparing SLC46A3 expression. In one embodiment, the control comprises a reference range of expression levels from control cells expressing SLC46A3, or a contemporaneous measurement of SLC46A3 expression in control cells known to express SLC46A3. This embodiment may be useful, for example, when the methods seek to identify reduced SLC46A3 relative to control. In another embodiment, the control may be a reference range of expression levels from control cells that do not express SLC46A3, or a contemporaneous measurement of SLC46A3 expression in control cells known not to express SLC46A3. This embodiment may be useful, for example, when the methods seek to identify cells that express SLC46A3. In another embodiment, the control may comprise a cohort of historical controls such as those profiled and publicly available through The Cancer Genome Atlas (TCGA) database, a reference level determined for a particular cancer type or subtype, or a reference level determined from an individual patient from an earlier timepoint. Those of skill in the art will recognize that other such controls can be used in the methods of the disclosure. 
     Any decrease in expression levels of SLC46A3 can improve susceptibility of the subject to lipid-based nanoparticle delivery. In various embodiments, the decrease in expression levels relative to historical control is at least 10%, 25%, 50%, 75%, 80%, 85%, 90%, or greater decrease in expression levels relative to control. 
     In one embodiment, the methods further comprise administering to a subject identified as susceptible to treatment with lipid-based nanoparticle therapies or identified as having cancer cells susceptible to treatment with nanoparticles, an amount effective to treat or diagnose cancer of a lipid-based cancer therapy nanoparticle. In this embodiment, the methods provide improved treatment and diagnostic methods by administering the lipid-based nanoparticle therapies to those subjects that will benefit from the administration. As will be understood by those of skill in the art based on the teachings herein, these methods can also be used to monitor therapy. Thus, in another embodiment the methods further comprise monitoring the lipid-based cancer therapy nanoparticle treatment in the subject, comprising determining expression levels at multiple time points of SLC46A3 in a plurality of cancer cells from a subject, wherein the expression levels at later time points relative to the expression level at earlier time points indicates an efficacy of the lipid-based cancer therapy nanoparticle in the subject. 
     In this embodiment: 
     (i) a reduced SLC46A3 expression level at later time points compared to earlier time points indicates an efficacy of the lipid-based nanoparticle delivery; or 
     (ii) an increased or unchanged SLC46A3 expression level at later time points compared to earlier time points indicates that the lipid-based nanoparticle delivery is unlikely to be effective. 
     Any suitable lipid-based nanoparticle therapy may be implicated in the methods of this embodiment, as deemed appropriate by attending medical personnel. In one embodiment of these embodiments, the lipid-based cancer therapy nanoparticle is selected from the lipid-based cancer therapy nanoparticles shown in Table 1. 
     In one embodiment, the subject has an increased or unchanged SLC46A3 expression level at the later time point compared to the earlier time point, wherein the method further comprises administering to the subject a non-lipid cancer therapy nanoparticle to treat or diagnose the cancer. In another embodiment, the subject has an increased or unchanged SLC46A3 expression level at the later time point compared to the earlier time point, wherein the method further comprises administering to the subject an increased dosage or total amount of the lipid-based cancer nanoparticle to treat or diagnose the cancer. 
     In a second aspect, the disclosure provides methods of treating cancer in a subject, the method comprising 
     (a) identifying a subject with cancer cells, such as malignant cells, that have a normal or increased SLC46A3 expression level as compared to historical controls, and 
     (b) delivering to said subject an amount effective to treat the cancer of:
         (i) a composition to decrease SLC46A3 expression; and   (ii) a lipid-based cancer therapy nanoparticle.       

     As disclosed above and in the examples, the inventors have identified SLC46A3 expression reduction as a means to improve lipid-based nanoparticle cancer therapies. Any suitable composition capable of decreasing SLC46A3 RNA and/or protein expression may be used, including but not limited to small molecules, proteins, SLC46A3 antibodies, inhibitory polypeptides, and/or inhibitory nucleic acids. Similarly, any suitable lipid-based cancer therapy nanoparticle may be used, including but not limited to those disclosed in Table 1. The composition to decrease SLC46A3 expression and the lipid-based cancer therapy nanoparticle may be administered together or separately, and may be administered at about the same time, simultaneously, or at different times. For example, the composition to decrease SLC46A3 expression could be dosed separately as a pre-treatment prior to administration of the lipid-based cancer therapy nanoparticle. 
     In one embodiment, the methods comprise delivering to the subject a lipid-based nanoparticle comprising the composition to decrease SLC46A3 expression and a chemotherapeutic to treat the cancer cells. In another embodiment, the composition to decrease SLC46A3 expression comprises SLC46A3-specific siRNA, shRNA, CRISPR, mRNA, miRNA, or oligonucleotides, or any other SLC46A3-specific inhibitory nucleic acid-based strategy. In a specific embodiment, the composition to decrease SLC46A3 expression is SLC46A3-specific siRNA. The sequence of the SLC46A3 gene is provided in SEQ ID NO:1 and the protein sequence is provided in SEQ ID NO:2. It is well within the level of skill in the art, based on the teachings herein, to generate SLC46A3-inhibitory nucleic acids or other SLC46A3 inhibitors (such as antibodies). 
     As used herein for all embodiments, “treat” or “treating” means accomplishing one or more of the following: (a) reducing the size or volume of tumors and/or metastases in the subject; (b) limiting any increase in the size or volume of tumors and/or metastases in the subject; (c) increasing survival or progression-free survival; (d) reducing the severity of symptoms associated with cancer; (e) limiting or preventing development of symptoms associated with cancer; and (0 inhibiting worsening of symptoms associated with cancer. 
     Any suitable lipid-based nanoparticle may be used in the methods of each aspect of the disclosure. In one embodiment, the lipid-based nanoparticle comprises a liposomal nanoparticle. As used herein, a liposomal nanoparticle is a spherical nanoparticle vesicle containing at least one lipid bilayer (hydrophobic membrane) surrounding an aqueous (hydrophilic) core. 
     In one embodiment, the liposomal nanoparticle comprises an anionic or neutral liposomal nanoparticle. In a specific embodiment, the liposomal nanoparticle comprises an anionic liposomal nanoparticle. Any suitable anionic or neutral liposomal nanoparticle may be used. 
     In one embodiment, the anionic liposomal nanoparticle comprises an electrostatic coating. Any suitable electrostatic coating may be used. In one embodiment, the electrostatic coating comprises poly-L-arginine (PLR). In various other embodiments, the electrostatic coating comprises one or more polyanions selected from the group consisting of polyacrylic acid (PAA), poly-L-aspartate (PLD), poly-L-glutamate (PLE), hyaluronate (HA), dextran sulfate (DXS), fucoidan (FUC), alginate (ALG), chondroitin sulfate (CS), carboxylate ions, and sulfate ions. In specific embodiments, the electrostatic coating comprises PLE and/or PLD. 
     In another embodiment, the liposomal nanoparticle comprises polyethylene glycol (PEG). Any suitable amount of PEG may be used in the lipid-based nanoparticles. In one embodiment, the PEG is present at between about 0.3 mol % and about 25 mol %. In other embodiments, the liposomal nanoparticle comprises PEG at between about 0.5 mol % and 25 mol %, about 1 mol % and 25 mol %, about 2.5 mol % and 25 mol %, or about 5 mol % and 25 mol %. 
     The examples provide extensive disclosure of specific lipid-based nanoparticle compositions. In one embodiment, the liposomal nanoparticle core comprises DSPC:DSPG:Cholesterol:DSPE, wherein DSPC is 1,2-distearoyl-sn-glycero-3-phosphocholine, DSPG is 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol), and DSPE is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine. In one such embodiment, the DSPC:DSPG:Cholesterol:DSPE are present in a molar ratio of about 31:31:31:6 mol %. In another embodiment, the liposomal nanoparticle core comprises DSPC:Cholesterol:DSPE-PEG(2000) carboxylic acid:DSPE; wherein PEG is polyethylene glycol and 2000 refers to the degree of polymerization. In one such embodiment, the DSPC:Cholesterol:DSPE-PEG(2000) carboxylic acid:DSPE are present in a molar ratio of about 55.67:33.3:5:6 6 mol %, or in a molar ratio of about 35.67:33.3:25:6 mol %. 
     In another embodiment, the liposomal nanoparticle core comprises DSPC:Cholesterol:PEG_PE:DSPE. In one such embodiment, the DSPC:Cholesterol:PEG_PE:DSPE are present in a molar ratio of about 53.8:39.9:0.3:6 mol %. 
     In one embodiment, the liposomal nanoparticle core comprises soy PC:cholesterol:PEG_PE:DSPE. In another such embodiment, the soy PC:cholesterol:PEG_PE:DSPE are present in a molar ratio of about 49:40:5:6 mol % 
     In a further embodiment, the liposomal nanoparticle comprises a composition as detailed in Table 2. 
     In another embodiment, the lipid-based nanoparticle comprises a solid lipid nanoparticle. As used herein, a “solid lipid nanoparticle” is a nanoparticle comprised of lipids, possessing a lipid core stabilized by surfactants that can encapsulate/solubilize therapeutic components, including but not limited to nucleic acids. In various embodiments, the solid lipid nanoparticle core comprises an ionizable, neutral, or cationic nanoparticle. In other embodiments, the solid lipid nanoparticle core comprises an ionizable, neutral, or cationic lipids, 
     In one embodiment, the solid lipid nanoparticle core comprises DLinMC3DMA:DSPC:DMG-PEG2000:cholesterol. In another embodiment, the DLinMC3DMA:DSPC:DMG-PEG2000:cholesterol are present in a molar ratio of about 50:10:1.5:38.5. In a further embodiment, the DLinMC3DMA:DSPC:DMG-PEG2000:cholesterol are present in a molar ratio of about 23.2:4.6:0.7:71.4 
     The lipid-based nanoparticle may be of any mean diameter wherein they are nanoparticles as defined herein. In one embodiment, liposomal nanoparticle comprises a mean diameter between about 50 nm and 200 nm. 
     In all embodiments, the lipid-based nanoparticle may be surface functionalized to include any “cargo” of interest. In one embodiment, the lipid-based nanoparticle may comprise a reactive group for covalent linkage of a cargo. Any suitable reactive group may be used, as is know to those of skill in the art. Any cargo suitable for an intended purpose may be used, including but not limited to a diagnostic, a therapeutic, a detectable molecule (i.e.: radioactive, fluorescent, luminescent, or other detectable group), etc. 
     For all methods of the disclosure, the subject may be any suitable subject that may benefit from the methods of the disclosure, including but not limited to mammalian subjects. In one embodiment, the subject is a human subject. 
     In a third aspect, the disclosure provides compositions for treating cancer, the composition comprising 
     (a) an inhibitor of SLC46A3 expression; and 
     (b) a lipid-based chemotherapeutic-containing nanoparticle. 
     The compositions may be used, for example, in the therapeutic methods of the disclosure. 
     In one embodiment, the inhibitor of SLC46A3 expression is selected from the group consisting of an SLC46A3-specific siRNA, shRNA, CRISPR, mRNA, miRNA, or oligonucleotide; or any other SLC46A3-specific inhibitory nucleic acid-based strategy. In a specific embodiment, the inhibitor of SLC46A3 expression comprises SLC46A3-specific siRNA. In one embodiment, the inhibitor of SLC46A3 expression is present within or on the chemotherapeutic-containing nanoparticle. 
     All embodiments and combinations of embodiments of the lipid-based nanoparticles disclosed for the method aspects of the disclosure are equally applicable in the compositions of the disclosure. 
     In a fourth aspect, the disclosure provides methods of identifying subjects suitable for enrollment in a clinical trial for nanoparticle cancer therapy, comprising the following steps: a) determining expression levels of SLC46A3 in a plurality of cells from multiple subjects diagnosed with cancer; 
     b) further determining whether the SLC46A3 expression levels from said patients are increased or decreased levels of expression as compared to historical controls, and c) identifying as subjects suitable for enrollment in a clinical trial for nanoparticle cancer therapy those patients with decreased SLC46A3 expression levels compared to historical controls. 
     All embodiments and combinations of embodiments disclosed for the first three aspects of the disclosure are applicable in this fourth aspect of the disclosure. 
     EXAMPLES 
     Summary 
     To accelerate the translation of cancer nanomedicine, we hypothesize that integrated genomic screens will improve understanding of the cellular processes governing nanoparticle trafficking. We developed a massively parallel high-throughput screening method leveraging barcoded, pooled cancer cell lines annotated with multi-omic data to investigate cell association patterns across a nanoparticle library spanning a range of formulations with clinical potential. This approach identified both the materials properties and cell-intrinsic features mediating nanoparticle-cell association. Coupling the data with machine learning algorithms, we constructed genomic nanoparticle trafficking networks and identified nanoparticle-specific biomarkers. We engineered cell lines to validate SLC46A3 as a biomarker whose expression inversely predicts liposomal nanoparticle uptake both in vitro and in vivo. Our work establishes the power of massively parallel pooled cell screens for nanoparticle delivery and enables the identification and utilization of biomarkers to rationally design nanoformulations for specific patient populations. 
     Nanoparticle (NP)-based therapeutics have enormous potential for personalized cancer therapy as they can encapsulate a range of therapeutic cargos including small molecules, biologics and, more recently, nucleic acids.(1, 2) Therapy-loaded NPs can be designed to prevent undesired degradation of the cargo, increase circulation time, and direct drugs specifically to target tumors. There have been notable successes in clinical translation of nanomedicines, including liposomal formulations of doxorubicin (Doxil) and irinotecan (Onivyde®).(3) These formulations extend the half-life of the active agent and have the potential to lower toxicity, but do not efficiently accumulate in tumors.(4, 5) 
     In the era of precision medicine, with the desire to deliver molecularly targeted and gene-based therapies to specific subcellular compartments within cancer cells, it is imperative to holistically probe the structure-function relationship of NPs as they relate to cellular interactions. 
     To comprehensively capture pan-cancer complexities and enable the statistical power to link NP association with cell intrinsic characteristics, we developed a competitive phenotypic screen to assess associations of a curated NP library across hundreds of cancer cell lines simultaneously. By pooling and plating 488 DNA barcoded cancer cell lines in a single well, we screened the interactions of a range of NP formulations with varied core compositions, surface chemistries, and diameters. We observed that NP core composition has a dominating influence on cell-specific interactions of the studied parameters. Coupling our biomarker findings with k-means clustering, we constructed genomic interaction networks associated with NP engagement, enabling the identification and connection of genes associated with the binding, recognition, and subcellular trafficking of distinct NP formulations. Moreover, through the use of univariate analyses and random forest algorithms, we identified that the gene SLC46A3 holds significant value as a predictive, NP-specific biomarker. We further validated SLC46A3 as a negative regulator of liposomal NP uptake in vitro and in vivo. The strategy outlined herein identifies cellular features underlying nanoparticle engagement, adding a new dimension to the study of cancer nanomedicine. 
     Screening Nanoparticle Association with Pooled Cell Lines 
     To screen hundreds of cancer cell lines simultaneously for NP-cancer cell line association patterns, we cultured pooled DNA-barcoded mixtures of cells (referred to herein as PRISM cells) and incubated them with fluorescent NPs. We then implemented a fluorescence-activated cell sorting (FACS) adaptive gating strategy to sort cell populations into four bins (quartiles, A-D) based on fluorescence signal as a proxy for the extent of NP-cell association. Experimental parameters were optimized to ensure sufficient cell number and barcode representation post-cell sorting and NPs were incubated for 4 and 24 hours. 
     For this screen, we designed a modular NP library to capture the effects of NP core composition, surface chemistry, and size on cell interactions. This panel of 35 NPs encompassed both clinical and experimental formulations. Specifically, anionic liposomes were formulated and electrostatically coated with cationic poly-L-arginine (PLR) followed by a series of polyanions. The polyanions were selected for their synthetic (polyacrylic acid, PAA), semisynthetic (poly-L-aspartate, PLD; poly-L-glutamate, PLE), or natural (hyaluronate, HA; dextran sulfate, DXS; fucoidan, FUC; alginate, ALG; chondroitin sulfate, CS) origin as well as the inclusion of both carboxylate and sulfate ions. These same electrostatic coatings were used to modify polymeric NP cores (polylactide-co-glycolide, PLGA) to test the effects of core composition on NP-cell interactions. We optimized formulations to obtain a diameter of approximately 100 nm for the liposome and PLGA formulations as the similar sizes would enable cross-core comparisons. We also included commercially manufactured fluorescent carboxylate- and sulfate-modified polystyrene (PS) nanoparticles in a range of diameters from 20-200 nm, enabling study of particle size and surface chemistry. Because of the clinical importance of polyethylene glycol (PEG)-containing formulations, PEGylated versions of liposome, PLGA, and PS particles were prepared, including the drug-free versions of two commercial formulations, liposomal doxorubicin (Doxil) and liposomal irinotecan (Onyvide®). The latter two formulations are denoted as LIPO-5% PEG* and LIPO-0.3% PEG*, respectively. All of the nanoparticles examined exhibited negative or neutral net charge, as the focus of this work is on systemic nanoparticle delivery systems. Positively charged nanoparticles have been shown to undergo nonspecific charge interactions with cells and proteins, leading to toxicity and premature clearance in vivo. Dynamic light scattering (DLS) was used to characterize the diameter, zeta potential, and polydispersity index (Tables 2-3) of this NP library. 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Nanoparticle formulation summary. Core compositions, polyelectrolyte identities 
               
               
                 and amounts used in the synthesis of the NP library are provided. 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                   
                   
                 Layer 
                 Layer 1- 
                 Layer 
                 Layer 2- 
               
               
                 Name 
                 Core 
                 Core Composition 
                 1 
                 Wt. Eq. 
                 2 
                 Wt. Eq. 
               
               
                   
               
               
                 LIPO - bare 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 — 
                 — 
                 — 
                 — 
               
               
                 LIPO - PLR 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 PLR 
                 0.3 
                 — 
                 — 
               
               
                 LIPO - PLD 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 PLR 
                 0.3 
                 PLD 
                 0.65 
               
               
                 LIPO- PLE 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 PLR 
                 0.3 
                 PLE 
                 0.65 
               
               
                 LIPO- PAA 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 PLR 
                 0.3 
                 PAA 
                 0.2 
               
               
                 LIPO - HA 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 PLR 
                 0.3 
                 HA 
                 1.2 
               
               
                 LIPO - ALG 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 PLR 
                 0.3 
                 ALG 
                 1.2 
               
               
                 LIPO - DXS 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 PLR 
                 0.3 
                 DXS 
                 0.65 
               
               
                 LIPO - FUC 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 PLR 
                 0.3 
                 FUC 
                 1.2 
               
               
                 LIPO - CS 
                 Liposome 
                 31:31:31:6 mol % DSPC:DSPG:Cholesterol:DSPE 
                 PLR 
                 0.3 
                 CS 
                 1.2 
               
               
                 LIPO - 5% PEG 
                 5% PEG 
                 55.67:33.3:5:6 mol % DSPC:Cholesterol:DSPE- 
                 — 
                 — 
                 — 
                 — 
               
               
                   
                 Liposome 
                 PEG(2000) carboxylic acid:DSPE 
               
               
                 LIPO - 25% PEG 
                 25% PEG 
                 35.67:33.3:25:6 mol % DSPC:Cholesterol:DSPE- 
                 — 
                 — 
                 — 
                 — 
               
               
                   
                 Liposome 
                 PEG(2000) carboxylic acid:DSPE 
               
               
                 LIPO - EGFR 
                 25% PEG 
                 35.67:33.3:25:6 mol % DSPC:Cholesterol:DSPE- 
                 — 
                 — 
                 — 
                 — 
               
               
                   
                 Liposome 
                 PEG(2000) carboxylic acid:DSPE 
               
               
                 LIPO - IGG 
                 25% PEG 
                 35.67:33.3:25:6 mol % DSPC:Cholesterol:DSPE- 
                 — 
                 — 
                 — 
                 — 
               
               
                   
                 Liposome 
                 PEG(2000) carboxylic acid:DSPE 
               
               
                 LIPO - 0.3% PEG* 
                 Onivyde 
                 53.8:39.9:0.3:6 mol % DSPC:Cholesterol:PEG_PE:DSPE 
                 — 
                 — 
                 — 
                 — 
               
               
                 LIPO - 5% PEG* 
                 Doxil 
                 49:40:5:6 mol % soy PC:cholesterol:PEG_PE:DSPE 
                 — 
                 — 
                 — 
                 — 
               
               
                 PLGA - bare 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 — 
                 — 
                 — 
                 — 
               
               
                 PLGA - PLR 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 PLR 
                 0.4 
                 — 
                 — 
               
               
                 PLGA - PLD 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 PLR 
                 0.4 
                 PLD 
                 0.65 
               
               
                 PLGA - PLE 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 PLR 
                 0.4 
                 PLE 
                 0.65 
               
               
                 PLGA - PAA 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 PLR 
                 0.4 
                 PAA 
                 0.2 
               
               
                 PLGA - HA 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 PLR 
                 0.4 
                 HA 
                 1.2 
               
               
                 PLGA - ALG 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 PLR 
                 0.4 
                 ALG 
                 1.2 
               
               
                 PLGA - DXS 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 PLR 
                 0.4 
                 DXS 
                 0.65 
               
               
                 PLGA - FUC 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 PLR 
                 0.4 
                 FUC 
                 1.2 
               
               
                 PLGA - CS 
                 PLGA 
                 Resomer RG502H Poly(D,L-lactide-glycolide) 
                 PLR 
                 0.4 
                 CS 
                 1.2 
               
               
                 PLGA - 50% PEG 
                 PEG-PLGA 
                 Poly(D,L-lactide-glycolide) 50:50-b-PEG 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-200nm COOH 
                 Polystyrene 
                 Yellow-green carboxylate-modified fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-100nm COOH 
                 Polystyrene 
                 Yellow-green carboxylate-modified fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-40nm COOH 
                 Polystyrene 
                 Yellow-green carboxylate-modified fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-20nm COOH 
                 Polystyrene 
                 Yellow-green carboxylate-modified fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-200nm SO3 
                 Polystyrene 
                 Yellow-green sulfate fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-20nm SO3 
                 Polystyrene 
                 Yellow-green sulfate fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-200nm PEG 
                 Polystyrene 
                 Yellow-green carboxylate-modified fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-100nm PEG 
                 Polystyrene 
                 Yellow-green carboxylate-modified fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-40nm PEG 
                 Polystyrene 
                 Yellow-green carboxylate-modified fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                 PS-20nm PEG 
                 Polystyrene 
                 Yellow-green carboxylate-modified fluosphere 
                 — 
                 — 
                 — 
                 — 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                 NP size, uniformity, and charge were measured using dynamic light scattering 
               
               
                 (DLS). Data is represented as the mean and standard deviation of three technical 
               
               
                 repeats, with the exception of formulations marked with a dagger (†). Size 
               
               
                 and PDI of these formulations were characterized using the Wyatt Dyna Pro Plate 
               
               
                 Reader, and only a single value for those measurements is presented. 
               
            
           
           
               
               
               
               
               
            
               
                   
                 Z-Average Size 
                 Number Mean Size 
                   
                 Zeta 
               
               
                 Name 
                 (nm) 
                 (nm) 
                 PDI 
                 Potential 
               
               
                   
               
               
                 LIPO - bare 
                 117.7 ± 4.0 
                  78.4 ± 7.2 
                 0.3 ± 0.1 
                 −45.0 ± 6.3 
               
               
                 LIPO - PLR 
                 154.4 ± 1.3 
                 104.5 ± 6.1 
                 0.1 ± 0.0 
                  53.6 ± 1.1 
               
               
                 LIPO - PLD 
                 132.3 ± 1.6 
                  92.2 ± 10.2 
                 0.1 ± 0.0 
                 −61.0 ± 1.1 
               
               
                 LIPO - PLE 
                 179.4 ± 0.7 
                 124.6 ± 7.0 
                 0.2 ± 0.0 
                 −47.2 ± 0.3 
               
               
                 LIPO - PAA 
                 136.8 ± 2.7 
                 104.0 ± 1.7 
                 0.1 ± 0.0 
                 −61.6 ± 1.4 
               
               
                 LIPO - HA 
                 159.7 ± 2.3 
                 111.2 ± 4.6 
                 0.1 ± 0.0 
                 −46.6 ± 0.8 
               
               
                 LIPO - ALG 
                 150.2 ± 4.0 
                 101.5 ± 3.0 
                 0.1 ± 0.0 
                 −78.7 ± 5.2 
               
               
                 LIPO - DXS 
                 133.2 ± 2.9 
                 108.7 ± 6.4 
                 0.1 ± 0.0 
                 −74.2 ± 2.5 
               
               
                 LIPO - FUC 
                 155.5 ± 3.9 
                  67.8 ± 37.5 
                 0.1 ± 0.0 
                 −61.2 ± 0.7 
               
               
                 LIPO - CS 
                 163.9 ± 3.7 
                 120.8 ± 1.3 
                 0.2 ± 0.0 
                 −61.9 ± 1.1 
               
               
                 LIPO - 5% PEG† 
                 — 
                 101.9 
                 0.2 
                 −53.1 ± 1.1 
               
               
                 LIPO - 25% PEG† 
                 — 
                  94.2 
                 0.2 
                 −46.0 ± 1.2 
               
               
                 LIPO - EGFR† 
                 — 
                 131.1 
                 0.3 
                 −45.2 ± 3.2 
               
               
                 LIPO - IGG† 
                 — 
                  99.2 
                 0.3 
                 −37.7 ± 2.7 
               
               
                 LIPO - 0.3% PEG* 
                 132.2 ± 1.6 
                  75.5 ± 2.1 
                 0.2 ± 0.0 
                 −50.2 ± 3.2 
               
               
                 LIPO - 5% PEG*† 
                 — 
                 106.2 
                 0.3 
                 −46.3 ± 1.6 
               
               
                 PLGA - bare 
                 175.4 ± 5.3 
                  117.7 ± 10.4 
                 0.1 ± 0.0 
                 −37.4 ± 0.8 
               
               
                 PLGA - PLR 
                 189.0 ± 4.3 
                 123.1 ± 7.5 
                 0.2 ± 0.0 
                  63.5 ± 0.4 
               
               
                 PLGA - PLD 
                 173.4 ± 3.1 
                 111.4 ± 1.9 
                 0.2 ± 0.0 
                 −53.0 ± 1.4 
               
               
                 PLGA - PLE 
                 157.8 ± 2.7 
                  88.6 ± 10.9 
                 0.2 ± 0.0 
                 −40.8 ± 0.9 
               
               
                 PLGA- PAA 
                 168.8 ± 4.2 
                 105.8 ± 4.0 
                 0.1 ± 0.0 
                 −62.8 ± 2.3 
               
               
                 PLGA - HA 
                 164.3 ± 4.1 
                  90.7 ± 32.8 
                 0.1 ± 0.0 
                 −45.0 ± 0.4 
               
               
                 PLGA - ALG 
                 197.1 ± 6.1 
                  116.0 ± 14.7 
                 0.2 ± 0.0 
                 −59.4 ± 1.4 
               
               
                 PLGA - DXS 
                  172.4 ± 10.5 
                 118.1 ± 6.8 
                 0.1 ± 0.0 
                 −61.7 ± 0.2 
               
               
                 PLGA - FUC 
                 172.1 ± 9.1 
                  96.8 ± 21.1 
                 0.2 ± 0.0 
                 −53.3 ± 2.2 
               
               
                 PLGA - CS 
                 205.0 ± 3.9 
                  93.2 ± 18.8 
                 0.2 ± 0.0 
                 −47.0 ± 2.4 
               
               
                 PLGA - 50% PEG 
                 170.3 ± 1.8 
                 104.5 ± 4.4 
                 0.2 ± 0.0 
                 −37.5 ± 0.8 
               
               
                 PS-200nm COOH 
                 204.3 ± 3.2 
                 172.0 ± 8.8 
                 0.1 ± 0.0 
                 −36.7 ± 2.5 
               
               
                 PS-100nm COOH 
                 123.2 ± 2.1 
                 102.9 ± 3.0 
                 0.0 ± 0.0 
                 −48.6 ± 2.6 
               
               
                 PS-40nm COOH 
                  65.7 ± 1.4 
                  48.7 ± 5.7 
                 0.1 ± 0.0 
                 −36.1 ± 1.3 
               
               
                 PS-20nm COOH 
                  79.0 ± 1.8 
                  35.4 ± 2.3 
                 0.3 ± 0.0 
                 −55.5 ± 1.9 
               
               
                 PS-200nm SO3 
                 257.6 ± 3.8 
                 223.7 ± 7.1 
                 0.1 ± 0.0 
                 −36.6 ± 0.6 
               
               
                 PS-20nm SO3 
                 118.8 ± 7.3 
                  35.2 ± 8.6 
                 0.3 ± 0.0 
                 −13.1 ± 0.4 
               
               
                 PS-200nm PEG 
                  303.8 ± 16.8 
                  202.6 ± 48.2 
                 0.3 ± 0.0 
                  −4.4 ± 2.9 
               
               
                 PS-100nm PEG 
                 125.9 ± 2.1 
                 100.5 ± 2.8 
                 0.1 ± 0.0 
                  −4.9 ± 0.6 
               
               
                 PS-40nm PEG 
                  97.2 ± 1.3 
                  67.3 ± 3.9 
                 0.1 ± 0.0 
                  −7.8 ± 0.5 
               
               
                 PS-20nm PEG 
                 131.8 ± 8.2 
                  51.3 ± 11.6 
                 0.3 ± 0.0 
                  −3.6 ± 0.5 
               
               
                   
               
            
           
         
       
     
     To ensure that our methods led to robust and meaningful data we selected an anti-epidermal growth factor receptor (EGFR) antibody as an active targeting control. A nonlethal EGFR antibody or IgG isotype control was covalently incorporated onto a liposome via a PEG tether. 
     After incubation with the NP library and fluorescence-activated cell sorting, cells were lysed, and the DNA barcodes were amplified, sequenced, and deconvoluted according to previously detailed protocols.(14, 27) After quality control analysis of technical (n=2) and biologic (n=3) replicates, all 488 cell lines met quality control measures and were carried forward for downstream analyses. 
     A probabilistic model was developed and applied to the data to infer the relative distribution of each cell line into the pre-determined bins (A-D) for each NP formulation. The probability of a cell from a given cell line falling into a given bin is used to represent those distributions, i.e., P A +P B +P C +P D =1. The technical details and the model&#39;s implementation are presented in the Supplementary Text section. Given the concordance of the inferred probabilities among the biologic replicates, we collapsed the replicates through their arithmetic average. Probabilities were then summarized using a weighting factor alpha (a) to calculate a weighted average (WA) for each NP-cell line pair: WA=−αP A −P B +P C +αP D  in which a higher WA implies higher NP-cell association and vice versa. We trialed a range of weighting factors (α=2, 10, 20 and 100) and found that downstream results were unchanged with the higher a values, and therefore, α=2 was used for subsequent analyses. 
     Cancer cells distinguish nanoparticles based on core composition Pearson-based unsupervised hierarchical clustering of pairwise WAs identified NP core material as a strong determinant of cell association, with the three core materials tested (liposomal, PLGA and PS) forming distinct clusters. This result was unexpected as we hypothesized surface chemistry to be a larger predictor of NP-cell interactions. Principal component analysis (PCA) similarly identified these core specific trends at both the 4 and 24 hour time points. Further analysis within each core material did reveal surface chemistry dependent trends, though they were more subtle than core-based clustering. 
     In contrast, no clusters were apparent when PCA was performed based on cell line, indicating that cancer cells of the same lineage did not have similar NP-association trends). Heterogeneity in NP-cell association in proliferating cells has been attributed to various aspects of cell growth and metabolism. To ensure that differential cell proliferation did not confound our results, we performed a parallel growth experiment with the same pooled cells and found no correlation between estimated doubling time and WA. 
     Cell-Intrinsic Features Mediate Nanoparticle Trafficking 
     We applied data from the Cancer Cell Line Encyclopedia (CCLE) to identify genomic features that act as predictive biomarkers for NP-cell association. To do this, we employed both univariate analyses and a random forest algorithm to correlate the baseline molecular features of each cell line (cell lineage; gene copy number; messenger RNA, microRNA, protein or metabolite abundance; function-damaging, hotspot or missense mutations) with NP association. 
     EGFR-Targeting Compounds Identify Relevant Biomarkers with High Confidence 
     Using univariate analysis for all CCLE features, we identified EGFR gene expression and protein abundance as the two most significantly correlated hits (q=4×10 −100  and q=4×10 −76 , respectively) with anti-EGFR antibody, but much less significantly (q=6×10 −9  and q=4×10 −10 , respectively) associated with the isotype control. 
     In EGFR-conjugated liposomes, these same hits were also identified more significantly (q=6×10 −21  and q=2×10 −18 , respectively) than the IgG control (q=3×10 −9  and q=3×10 −6 , respectively). The statistical significance of EGFR biomarkers was lower for the antibody-conjugated liposome than the free antibody, which may be due to steric blockage introduced by covalently linking an antibody to a NP surface that may interfere with binding to its target. Thus, we demonstrated the ability to quantitatively compare expected biomarker targets of both free antibodies and antibody-conjugated NPs using our platform. This method of analysis will provide therapeutic insights in the design of antibody-drug conjugates, specifically in evaluating the effects of conjugation site or linker chemistry. 
     Biomarker Number and Significance are Influenced by Nanoparticle Properties 
     We employed univariate analysis to correlate association and CCLE features for each NP formulation, thresholding q-values less than 1×10 −10 . Selection of this cutoff was guided by the IgG-conjugated antibody analysis, which returned few hits above this threshold. For liposomal NPs, we observed that the number of significant biomarkers was higher at 4 h than 24 h. We believe this may be indicative of active uptake processes, established to take place within the first few hours of NP-cell interactions, whereas at 24 hours, we may be capturing features associated with less specific interactions. We also observed that liposome surface modification influences the number and significance of biomarkers. Specifically, liposomes electrostatically coated with polysaccharides (HA, ALG, DXS, FUC, CS) had the highest amount of associated biomarkers, which we hypothesize is due to the high degree of interactions between sugars and cell surface proteins as well as the potential for naturally occurring polysaccharides to interact with a wide range of cell surface elements. In line with this hypothesis, the addition of PEG, a well-established antifouling polymer, reduces the number and significance of associated biomarkers almost to zero. In contrast to the highly specific hits generated from EGFR-conjugated liposomes (formulated using 25% PEG liposomes), this abrupt decrease in significant biomarkers further indicates the ability of our platform to identify specific NP binding and recognition elements. In contrast to the liposomal formulations, PLGA formulations, regardless of surface modification, resulted in few biomarkers at either time point. Lastly, a high number of significant biomarkers was associated with both carboxylated and sulfated PS NPs included in our screen, though there was no time dependence, in contrast to the liposomal formulation. While this result was initially surprising, as the PS formulations are made of synthetic polystyrene polymers, meaningful biological interactions with anionic polystyrenes, both in polymer and particle form, have been reported. Specifically, it was described that these systems have the appropriate mix of hydrophobicity and anionic charge character to interact favorably with trafficking proteins, including the caveolins. 
     NP Biomarkers are Connected and Create Trafficking Networks 
     We additionally identified predictive biomarkers for the tested NP formulations using a random-forest algorithm. We annotated these candidate biomarkers to include the categories of gene expression, gene copy number, or protein abundance. Data from the 4 h time point was chosen for this analysis based on the EGFR-related hits for liposomes, which were more significant at 4 h than at 24 h. As we were interested in applying this approach to identify cellular features positively correlated with uptake (e.g., increased expression of trafficking proteins), hits negatively correlated with NP association were removed from this analysis. Next, we used K-means clustering to visualize biomarkers based on their relative importance and presence across formulations. Clusters 1 and 2 contained many hits shared across NP formulations and were especially enriched for liposomal and PS NPs. These 205 genes and proteins were input into a database(40-42) to generate a protein-protein interaction (PPI) network that was found to be highly interconnected (PPI enrichment p-value &lt;1×10 −16 ). Notably, the network is enriched in proteins found in the plasma membrane, extracellular region, and extracellular matrix (false discovery rate [FDR]=8×10 −12 , 3×10 −9 , and 3×10 −8 , respectively) based on enrichment analysis with gene ontology (GO) localization datasets.(43-45) The identification of overlapping biomarkers that are localized to the cell surface and have established protein-protein interactions led us to hypothesize that these proteins are important in early NP trafficking. Enrichment analyses using GO molecular functions datasets showed enrichment in numerous binding processes, giving further credence to this theory. These results serve as a framework for the comprehensive investigation of cellular processes important for NP engagement, which may prove useful for fundamental trafficking studies and target identification. 
     SLC46A3 is a Negative Regulator of Liposomal NP Uptake 
     Evaluating univariate results across NP formulations, we identified one biomarker with a strong, inverse relationship with liposomal NP association: expression of solute carrier family 46 member 3 (SLC46A3), a lysosomal transporter. This is, to our knowledge, the first description of SLC46A3 as a NP-specific biomarker. We sought to validate the predictive power of SLC46A3 expression for liposomal NP association. 
     SLC46A3 expression was the most significant hit on univariate analysis and also the top ranked random forest feature for each liposomal NP tested at 24 h, regardless of surface modification ( FIGS. 1A and 5 ). This inverse relationship between SLC46A3 expression and NP association was found to be specific to liposomal NPs, and not observed with PLGA or PS NPs, and was maintained regardless of cancer cell lineage ( FIGS. 1B and 5 ). 
     We selected nine cancer cell lines from the pool and four additional cell lines, spanning multiple lineages, with a range of native SLC46A3 expression levels for screening in a non-pooled fashion ( FIG. 1C-D ). Analogous to the pooled screen, individual cell lines were profiled using flow cytometry and NP-associated fluorescence was quantified after 24 h incubation ( FIGS. 13D and 6 ). In line with observations from pooled screening, the inverse relationship between liposome association and native SLC46A3 expression was maintained, suggesting that SLC46A3 may play a key role in trafficking of liposomal NPs. 
     To further functionally probe whether SLC46A3 expression level governs NP association, we selected two cancer cell lines from the pooled screen that displayed strong phenotypes ( FIG. 2A ). The melanoma cell line LOXIMVI exhibited high association and breast cancer cell line T47D exhibited low association with liposomal NP formulations ( FIG. 2B ). We developed a toolkit using these cell lines by knocking out SLC46A3 in T47D cells and inducing overexpression in LOXIMVIs ( FIGS. 7A-H ). 
     As SLC46A3 is a protein associated with lysosomal membranes, we utilized LysoTracker® dye to evaluate the effect of SLC46A3 modulation on endolysosomal compartments in both T47D and LOXIMVI engineered cell lines ( FIG. 2C ). We observed an SLC46A3 expression level-dependent change: cells with higher SLC46A3 levels (T47D-vector control, LOXIMVI-SLC46A3 OE) exhibited more brightly dyed endolysosomal compartments compared to their low SLC46A3 expression counterparts (T47D-SLC46A3 knockout, LOXIMVI-vector control). 
     Overexpression of SLC46A3 in LOXIMVI cells significantly abrogated interaction with bare liposomes (p=0.006) using flow cytometry profiling ( FIG. 2D ). The T47D-SLC46A3 knockout cell line demonstrated significantly increased association with bare liposomes compared to parental or vector control lines (p=0.0017,  FIG. 2D ). We further confirmed that these trends are generalizable across a range of surface functionalized liposomes ( FIG. 2E ). Moreover, no significant changes in NP association were observed for PLGA and PS NPs. We also confirmed that the presence of serum proteins in cell culture media does not abrogate this trend ( FIG. 71 ). Taken together, these data indicate modulation of SLC46A3 alone in cancer cells is sufficient to negatively regulate association and uptake of liposomal NPs. 
     As flow cytometry does not provide spatial information with respect to NP-cell interactions, we employed imaging cytometry to characterize NP localization in a high throughput manner ( FIG. 3A-F ). We selected four representative formulations: three liposomal NPs to probe the relationship of SLC46A3 expression with liposome trafficking; and one PLGA NP formulation with a common outer layer. 
     Consistent with trends observed by flow cytometry, we observed an inverse relationship between NP intensity and SLC46A3 expression for liposomal, but not PLGA, NPs ( FIG. 3A-B ). Using brightfield images, we applied a mask to investigate cellular localization of NPs. All tested formulations were internalized, and this did not change with SLC46A3 modulation ( FIG. 3C-D ), so we hypothesize that SLC46A3 plays a role in retention of NPs rather than directly blocking uptake. 
     We investigated localization of NPs by scoring NP signal based on distribution within each cell ( FIG. 3E-F ). We observed stark differences in median cellular distribution scores of liposomal NPs in relation to SLC46A3 expression levels in T47D cells. This was not observed for PLGA NPs, mimicking the previously observed core-specific relationship between NP-cell association and SLC46A3 expression. Changes in this score, though less pronounced, were also observed for liposomal NPs in LOXIMVI cells. 
     To confirm these findings with higher spatial resolution, we employed deconvolution microscopy of live cells and incorporated a lysosomal stain to observe changes in intracellular trafficking ( FIG. 3G-H ). NPs appeared uniformly distributed within T47D-SLC46A3 KO cells, co-localizing with endolysosomal vesicles. In contrast, LIPO-PLD NPs were localized to large endolysosomal clusters in T47D-vector control cells. This trend was also observed for LIPO-PLE and LIPO-0.3% PEG* NPs and at the earlier time point of 4 h ( FIG. 8 ). Changes in localization were not observed for the tested PLGA PLD NPs. This again indicates a NP core-dependent relationship with SLC46A3. 
     In the engineered LOXIMVI cell lines, we also observed co-localization of liposomal NPs with endolysomal signal. However, predictable changes in NP localization were not detected, in line with smaller changes in median cellular distribution scores. Taken together, these results suggest that the relationship between SLC46A3 expression and NP uptake is twofold: SLC46A3 predictably and negatively regulates the amount of liposomal NPs accumulating within a cell and modulates subcellular trafficking in certain contexts. 
     Knockdown of SLC46A3 with siRNA Leads to Predictable Changes in NP Delivery 
     We have shown that knockout of SLC46A3 using CRISPR/Cas9 leads to increased nanoparticle-cell association for liposomes. Knocking down SLC46A3 expression with small interfering RNA (siRNA) results in a statistically significant increase in nanoparticle-cell association (p&lt;0.001). The data is provided in Table 4, further confirming the genotype-phenotype relationship of SLC46A3 and liposomal nanoparticle delivery. 
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 Nanoparticle association expressed as MFI in the T47D cell line after 24 hr 
               
               
                 treatment with siRNA directed against SLC46A3 or scrambled siRNA control. 
               
            
           
           
               
               
               
               
               
               
            
               
                   
                   
                 Median fluorescence 
                 Standard 
                   
                 P value, 
               
               
                 siRNA Treatment 
                 NP Treatment 
                 intensity (MFI) 
                 Deviation 
                 n 
                 2-tailed 
               
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 siRNA_SLC46A3 
                 0.3% PEG Liposome 
                 11692.86 
                 1366.55 
                 7 
                 0.0006 
               
               
                 siScramble 
                 0.3% PEG Liposome 
                 5398.43 
                 1876.48 
                 7 
               
               
                 siRNA_SLC46A3 
                 No nanoparticle 
                 87.80 
                 1.93 
                 3 
                 &gt;0.05 
               
               
                 siScramble 
                 No nanoparticle 
                 87.40 
                 0.00 
                 3 
               
               
                   
               
            
           
         
       
     
     Liposome Retention and Accumulation Remains SLC46A3-Dependent In Vivo 
     To evaluate the potential clinical utility of SLC46A3 as a negative regulator of liposomal NP delivery, we tested in vivo delivery of an FDA-approved nanoparticle analog, the drug-free version of liposomal irinotecan (LIPO-0.3% PEG*), in mice bearing subcutaneous LOXIMVI flank tumors. NPs were administered via a one-time intratumoral (IT) injection or repeat intravenous (IV) administration to evaluate tumor retention and accumulation, respectively ( FIG. 4A ,  FIG. 9 ). 
     NP signal was quantified both 4 and 24 h following IT administration. In line with our hypothesis, as well as in vitro NP-associated fluorescence data ( FIG. 9A ), we observed an inverse relationship between SLC46A3 expression and LIPO-0.3% PEG* NP retention that became more pronounced over time (p=0.0115, 4 h; p=0.0002, 24 h) ( FIG. 4C-D ,  FIG. 9B-E ). Moreover, these findings also align with our initial findings, in which SLC46A3 expression was a more significant biomarker at 24 h (q-value=3.49×10 −30 , Table 3,  FIG. 5 ) than at 4 h (q-value=1.47×10 −4 , Table 3,  FIG. 5 ). 
     To determine if this newly identified biomarker can be used to predictably govern accumulation of non-targeted NPs, which bear no specific functional ligands on their surface, following systemic administration, we quantified NP signal following IV injections. Notably, we observed a significant relationship between SLC46A3 and NP accumulation (p=0.0019) ( FIG. 4D ,  FIG. 9F ). This demonstrates the predictive power of SLC46A3 as a NP specific biomarker that holds true even in complex physiologic settings. 
     Together, these data highlight the real-world relevance of the screening assay in general as well as the utility of SLC46A3 in particular a clinically actionable biomarker. 
     SLC46A3 Expression Predicts mRNA Delivery Efficacy Via Solid Lipid Nanoparticles 
     Given the strong relationship between SLC46A3 expression and liposomal nanoparticles, we hypothesized that the relationship would hold true for other lipid-based nanoparticles. Indeed, SLC46A3 expression is predictive of improved transfection via solid lipid nanoparticles containing messenger RNA encoding green fluorescent protein (GFP mRNA). Transfection efficiency as measured by median GFP fluorescence or % of cells GFP positive is decreased in LOXIMVI cells engineered to overexpress SLC46A3 compared to control. Data is shown in Table 5 
     
       
         
           
               
             
               
                 TABLE 5 
               
               
                   
               
               
                 Transfection of engineered LOXIMVI cells after lipid nanoparticle 
               
               
                 delivery of GFP mRNA. Transfection is measured by median 
               
               
                 GFP fluorescence and % GFP positive cells. LNP1 formulation 
               
               
                 is 50:10:1.5:38.5 DLinMC3DMA:DSPC:DMG-PEG2000:cholesterol; 
               
               
                 LNP2 formulation is 23.2:4.6:0.7:71.4 DLinMC3DMA:DSPC:DMG- 
               
               
                 PEG2000:cholesterol. The N:P was held constant at 6 and 
               
               
                 all cells were dosed for 24 hours. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                   
                 LOXIMVI control 
                 LOXIMVI SLC46A3 OE 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 LNP 
                 mRNA dose 
                 Median GFP 
                   
                   
                 Median GFP 
                   
                   
               
               
                 Formulation 
                 (ng) 
                 Intensity 
                 Std Dev 
                 N 
                 Intensity 
                 Std Dev 
                 N 
               
               
                   
               
               
                 None 
                 0 
                 17.1 
                 0.8 
                 3 
                 17.1 
                 0.8 
                 3 
               
               
                 LNP1 
                 200 
                 2366.5 
                 1243.8 
                 2 
                 530.0 
                 167.4 
                 3 
               
               
                   
                 100 
                 435.0 
                 145.7 
                 2 
                 127.7 
                 13.1 
                 3 
               
               
                   
                 50 
                 90.5 
                 26.2 
                 2 
                 105.5 
                 33.3 
                 3 
               
               
                 LNP2 
                 200 
                 640.3 
                 31.0 
                 3 
                 408.0 
                 52.3 
                 2 
               
               
                   
                 100 
                 270.7 
                 92.2 
                 3 
                 183.5 
                 30.4 
                 2 
               
               
                   
                 50 
                 193.3 
                 33.4 
                 3 
                 102.6 
                 16.1 
                 2 
               
               
                   
               
            
           
           
               
               
               
            
               
                   
                 LOXIMVI control 
                 LOXIMVI SLC46A3 OE 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 LNP 
                 mRNA dose 
                 % GFP 
                   
                   
                 % GFP 
                   
                   
               
               
                 Formulation 
                 (ng) 
                 positive 
                 Std Dev 
                 N 
                 positive 
                 Std Dev 
                 N 
               
               
                   
               
               
                 None 
                 0 
                 0.1 
                 0.0 
                 3 
                 0.0 
                 0.0 
                 3 
               
               
                 LNP1 
                 200 
                 98.5 
                 0.5 
                 2 
                 93.0 
                 2.8 
                 3 
               
               
                   
                 100 
                 90.9 
                 5.3 
                 2 
                 62.3 
                 4.1 
                 3 
               
               
                   
                 50 
                 49.7 
                 10.1 
                 2 
                 53.4 
                 11.0 
                 3 
               
               
                 LNP2 
                 200 
                 93.5 
                 0.6 
                 3 
                 89.3 
                 0.1 
                 2 
               
               
                   
                 100 
                 81.9 
                 7.8 
                 3 
                 71.6 
                 3.5 
                 2 
               
               
                   
                 50 
                 71.1 
                 3.9 
                 3 
                 54.0 
                 5.3 
                 2 
               
               
                   
               
            
           
         
       
     
     Discussion and Conclusions 
     This work represents the first high-throughput interrogation of NP-cancer cell interactions through the lens of multi-omics. Harnessing the power of pooled screening and high throughput sequencing, we developed and validated a platform to identify predictive biomarkers for NP interactions with cancer cells. We utilized this platform to screen a 35 member NP library against a panel of 488 cancer cell lines. This enabled the comprehensive study and identification of key parameters mediating NP-cell interactions, highlighting the importance of considering both nanomaterials and cellular features in concert. 
     Moreover, through the use of univariate analyses and random forest algorithms, we identified biomarkers correlated with NP association. The robust and quantitative nature with which we detected EGFR hits for antibody-targeted NPs shows the utility of this platform for the development and optimization of antibody-targeted therapeutics. 
     By clustering NP-specific biomarkers across formulations, we constructed interaction networks, identifying and connecting genes associated with NP binding, recognition, and subcellular trafficking. This provides the scientific community with a blueprint for the fundamental study of cellular processes mediating NP engagement, with applications for both basic and translational research. 
     We additionally identified gene expression of SLC46A3 as a negative regulator of liposomal NP uptake. We validated these findings in a panel of non-pooled cell lines and engineered cell lines with modulated SLC46A3 levels. Importantly, as all current FDA approved NPs for anticancer applications are liposomal formulations, there is significant potential for this biomarker to be quickly implemented in clinical studies with existing, approved formulations. To this end, we recapitulated our findings in an in vivo model using an analog of an FDA-approved liposomal NP formulation. Our findings present the key first step toward identifying and utilizing such NP-specific biomarkers. 
     In summary, we present a powerful platform to study NP-cancer cell interactions simultaneously through the use of pooled screening, genomics, and machine learning algorithms. This provides a new dimension to the study of cancer nanomedicine. Application of this platform will serve useful not only for the rational design of nanocarriers, but also for the identification of specific phenotypes primed to benefit from targeted drug delivery and nanomedicine. 
     REFERENCES AND NOTES 
     
         
         1. J. J. Shi, P. W. Kantoff, R. Wooster, 0. C. Farokhzad, Cancer nanomedicine: progress, challenges and opportunities.  Nat. Rev. Cancer  17, 20-37 (2017). 
         2. M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, R. Langer, Engineering precision nanoparticles for drug delivery.  Nat. Rev. Drug. Discov.  20, 101-124 (2020). 
         3. S. Tran, P. J. DeGiovanni, B. Piel, P. Rai, Cancer nanomedicine: a review of recent success in drug delivery.  Clin. Transl. Med.  6, 1-21 (2017). 
         4. S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak, W. C. W. Chan, Analysis of nanoparticle delivery to tumours.  Nat. Rev. Mater.  1, 16014 (2016). 
         5. Y. H. Cheng, C. L. He, J. E. Riviere, N. A. Monteiro-Riviere, Z. M. Lin, Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach.  ACS Nano  14, 3075-3095 (2020). 
         6. Y. S. Youn, Y. H. Bae, Perspectives on the past, present, and future of cancer nanomedicine.  Adv. Drug Deliver. Rev.  130, 3-11 (2018). 
         7. W. Poon, B. R. Kingston, B. Ouyang, W. Ngo, W. C. W. Chan, A framework for designing delivery systems.  Nat. Nanotechnol.  15, 819-829 (2020). 
         8. W. Poon, Y. N. Zhang, B. Ouyang, B. R. Kingston, J. L. Y. Wu, S. Wilhelm, W. C. W. Chan, Elimination Pathways of Nanoparticles.  ACS Nano  13, 5785-5798 (2019). 
         9. S. Correa et al., Tuning Nanoparticle Interactions with Ovarian Cancer through Layer-by-Layer Modification of Surface Chemistry.  ACS Nano  14, 2224-2237 (2020). 
         10. N. Boehnke, S. Correa, L. Hao, W. Wang, J. P. Straehla, S. N. Bhatia, P. T. Hammond, Theranostic Layer-by-Layer Nanoparticles for Simultaneous Tumor Detection and Gene Silencing.  Angew. Chem. Int. Ed. Engl.  59, 2776-2783 (2020). 
         11. N. Boehnke, K. J. Dolph, V. M. Juarez, J. M. Lanoha, P. T. Hammond, Electrostatic Conjugation of Nanoparticle Surfaces with Functional Peptide Motifs.  Bioconjug. Chem.  31, 2211-2219 (2020). 
         12. J. E. Dahlman et al., Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics.  Proc. Natl. Acad. Sci. U.S.A.  114, 2060-2065 (2017). 
         13. B. Nogrady, How cancer genomics is transforming diagnosis and treatment.  Nature  579, S10-S11 (2020). 
         14. C. N. Yu et al., High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines.  Nat. Biotechnol.  34, 419-423 (2016). 
         15. S. M. Corsello et al., Discovering the anticancer potential of non-oncology drugs by systematic viability profiling.  Nat. Cancer  1, 235-248 (2020). 
         16. S. Correa, N. Boehnke, E. Deiss-Yehiely, P. T. Hammond, Solution Conditions Tune and Optimize Loading of Therapeutic Polyelectrolytes into Layer-by-Layer Functionalized Liposomes.  ACS Nano  13, 5623-5634 (2019). 
         17. S. Correa et al., Highly Scalable, Closed-Loop Synthesis of Drug-Loaded, Layer-by-Layer Nanoparticles.  Adv. Funct. Mater.  26, 991-1003 (2016). 
         18. Z. J. Deng, S. W. Morton, E. Ben-Akiva, E. C. Dreaden, K. E. Shopsowitz, P. T. Hammond, Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment.  ACS Nano  7, 9571-9584 (2013). 
         19. S. W. Morton, Z. Y. Poon, P. T. Hammond, The architecture and biological performance of drug-loaded LbL nanoparticles.  Biomaterials  34, 5328-5335 (2013). 
         20. G. Decher, Fuzzy nanoassemblies: Toward layered polymeric multicomposites.  Science  277, 1232-1237 (1997). 
         21. E. C. Dreaden et al., Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.  Clin. Cancer Res.  21, 4410-4419 (2015). 
         22. E. C. Dreaden, S. W. Morton, K. E. Shopsowitz, J. H. Choi, Z. J. Deng, N. J. Cho, P. T. Hammond, Bimodal Tumor-Targeting from Microenvironment Responsive Hyaluronan Layer-by-Layer (LbL) Nanoparticles.  ACS Nano  8, 8374-8382 (2014). 
         23. O. P. Oommen, C. Duehrkop, B. Nilsson, J. Hilborn, O. P. Varghese, Multifunctional Hyaluronic Acid and Chondroitin Sulfate Nanoparticles: Impact of Glycosaminoglycan Presentation on Receptor Mediated Cellular Uptake and Immune Activation.  ACS Appl. Mater. Inter.  8, 20614-20624 (2016). 
         24. J. S. Suk, Q. G. Xu, N. Kim, J. Hanes, L. M. Ensign, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.  Adv. Drug Deliver. Rev.  99, 28-51 (2016). 
         25. E. Frohlich, The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles.  Int. J. Nanomed.  7, 5577-5591 (2012). 
         26. E. A. Berg, J. B. Fishman, Labeling Antibodies Using N-Hydroxysuccinimide (NHS)-Fluorescein.  Cold Spring Harb. Protoc.  3, 229-231 (2019). 
         27. X. Jin et al., A metastasis map of human cancer cell lines.  Nature  588, 331-336 (2020). 
         28. J. A. Kim, C. Aberg, A. Salvati, K. A. Dawson, Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population.  Nat. Nanotechnol.  7, 62-68 (2012). 
         29. C. Aberg, J. A. Kim, A. Salvati, K. A. Dawson, Reply to ‘The interface of nanoparticles with proliferating mammalian cells’.  Nat. Nanotechnol.  12, 600-603 (2017). 
         30. E. Panet et al., The interface of nanoparticles with proliferating mammalian cells.  Nat. Nanotechnol.  12, 598-600 (2017). 
         31. P. Rees, J. W. Wills, M. R. Brown, C. M. Barnes, H. D. Summers, The origin of heterogeneous nanoparticle uptake by cells.  Nat. Commun.  10 (2019). 
         32. J. Barretina et al., The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (vol 483, pg 603, 2012).  Nature  492, 290-290 (2012). 
         33. M. Ghandi et al., Next-generation characterization of the Cancer Cell Line Encyclopedia.  Nature  569, 503-508 (2019). 
         34. K. Tsuchikama, Z. Q. An, Antibody-drug conjugates: recent advances in conjugation and linker chemistries.  Protein Cell  9, 33-46 (2018). 
         35. J. Rejman, V. Oberle, I. S. Zuhorn, D. Hoekstra, Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis.  Biochem. J.  377, 159-169 (2004). 
         36. S. Behzadi et al., Cellular uptake of nanoparticles: journey inside the cell.  Chem. Soc. Rev.  46, 4218-4244 (2017). 
         37. Y. Shamay et al., P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.  Sci. Transl. Med.  8, 345 (2018). 
         38. G. Saravanakumar, D. G. Jo, J. H. Park, Polysaccharide-Based Nanoparticles: A Versatile Platform for Drug Delivery and Biomedical Imaging.  Curr. Med. Chem.  19, 3212-3229 (2012). 
         39. J. Voigt, J. Christensen, V. P. Shastri, Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae.  Proc. Natl. Acad. Sci. U.S.A.  111, 2942-2947 (2014). 
         40. D. Szklarczyk et al., STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.  Nucleic Acids Res.  47, D607-D613 (2019). 
         41. C. von Mering, M. Huynen, D. Jaeggi, S. Schmidt, P. Bork, B. Snel, STRING: a database of predicted functional associations between proteins.  Nucleic Acids Res.  31, 258-261 (2003). 
         42. B. Snel, G. Lehmann, P. Bork, M. A. Huynen, STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene.  Nucleic Acids Res.  28, 3442-3444 (2000). 
         43. D. Martin, C. Brun, E. Remy, P. Mouren, D. Thieffry, B. Jacq, GOToolBox: 
       
    
     functional analysis of gene datasets based on Gene Ontology.  Genome Biol.  5, R101 (2004).
     44. M. Ashburner et al., Gene Ontology: tool for the unification of biology.  Nat. Genet.  25, 25-29 (2000).   45. S. Carbon et al., The Gene Ontology resource: enriching a GOld mine.  Nucleic Acids Res.  49, D325-D334 (2021).   46. K. J. Hamblett et al., SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.  Cancer Res.  75, 5329-5340 (2015).   47. C. K. Tsui et al., CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity.  Nat. Chem. Biol.  15, 949-958 (2019).   48. K. Kinneer et al., SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.  Clin. Cancer Res.  24, 6570-6582 (2018).   49. Q. Zhao et al., Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.  Biomed. Pharmacother.  114, 108864 (2019).   50. G. M. Li et al., Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.  Mol. Cancer Ther.  17, 1441-1453 (2018).   51. C. H. Adelmann et al., MFSD12 mediates the import of cysteine into melanosomes and lysosomes.  Nature  588, 699-704 (2020).   52. S. Stern, B. Neun, NCL Method GTA-12 . NCI Hub , doi:10.17917/YPTH-N396.   53. M. Stephens, False discovery rates: a new deal.  Biostatistics  18, 275-294 (2017).   54. R Core Team, R: A language and envrionemnt for statistical computing. R Foundation for Statistical Compouting. https://www.R-project.org/.   55. H. Wickham, ggplot2: Elegant Graphics for Data Analysis. Use R, 1-212 (2009).   56. Y. Tang, M. Horikoshi, W. X. Li, ggfortify: Unified Interface to Visualize Statistical   

     Results of Popular R Packages.  R. J.  8, 474-485 (2016).
     57. M. Horikoshi, Y. Tang, ggfortify: Data Visualization Tools for Statistical Analysis Results. https://CRAN.R-project.org/package=ggfortify (2016).   

     Supplemental Information 
     Materials and Methods 
     Materials 
     Reagents 
     1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt) (DSPG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (chloride salt) (18:1 EPC), L-α-phosphatidylcholine (Soy-PC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (sodium salt) (MPEG-2k-DSPE, for Ab liposomes), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (ammonium salt) (PEG_PE), and cholesterol were purchased from Avanti Polar Lipids. Sulfo-cyanine5 NHS ester and cyanine5 free acid were purchased from Lumiprobe. Methoxy PEG amine (HCl salt), MW 2000 Da (for PS PEGylation) was purchased from JenKem Technologies. Chloroform and methanol were purchased from TCI and Sigma, respectively. Poly(D,L-lactide-glycolide) (Resomer RG502H, 7 kDa:17 kDa) and Poly(D,L-lactide-glycolide) 50:50-b-PEG (10 kDa PLGA, 2 kDa PEG) were purchased from Sigma. 
     Non-glycosylated monoclonal human IgG1 antibody against human EGFR (hegfr-mab12, lot: EG12-39-01) and isotype control—Human IgG1 (bgal-mabl, lot: BG1-41-01) were purchased from InvivoGen. Human EGFR (Research Grade Cetuximab Biosimilar) antibody was purchased from R&amp;D Biosystems. Poly-L-arginine hydrochloride (PLR200, 38.5 kDa), poly-L-aspartic acid sodium salt (PLD100, 14 kDa), and poly-L-glutamic acid sodium salt (PLE100, 15 kDa) were purchased from Alamanda Polymers. Sodium hyaluronate (40 kDa) was purchased from Lifecore Biomedical. Dextran sulfate (15 kDa), fucoidan (from fucus vesiculosus), and polyacrylic acid (8 kDa) were purchased from Sigma. Sodium alginate was purchased from NovaMatrix. Chondroitin sulfate A (10-30 kDa average MW) was purchased from Carbosynth Ltd. Yellow-green fluorescent polysytrene microspheres (Fluospheres), 5 M bioreagent grade NaCl solution, and 1 M bioreagent-grade HEPES were purchased from Fisher Scientific. 
     Whatman nuclepore polycarbonate hydrophilic membranes (400, 200, 100 and 50 nm sizes) were purchased from GE. All glassware was obtained from Chemglass. 5 mL Falcon brand round-bottom tubes with 35 μm cell strainer cap, 50/15 mL Falcon tubes and 50/5/2 mL DNA/Protein Eppendorf tubes were purchased from VWR. D02-E100-05-N and C02-E100-05-N tangential flow filtration filters were purchased from Repligen. Polystyrene semi-micro cuvettes for the Malvern Zetasizer™ were purchased from VWR and DTS1070 folded capillary cells were purchased directly from Malvern. Black, glass bottom 364 well plates for the Wyatt DLS were purchased directly from the Peterson (1957) Nanotechnology Core Facility. 
     RPMI-1640 (Invitrogen/Corning), and PBS solution pH 7.4 (Gibco) were purchased from Fisher Scientific. Heat inactivated fetal bovine serum (FBS), Tween20, Igepal™ CA-630, Trizma hydrochloride, and Potassium chloride solution (˜1 M in H 2 O) were purchased from Sigma. Proteinase K was purchased from Qiagen. Matrix Storage Blocks (96 well, 1 mL) were purchased from ThermoFisher. Tissue culture plasticware, trypsin EDTA, Accutase, and penicillin streptomycin were purchased from Corning. LabTek 8-chamber coverslips (cat. no. 155409), CellTracker™ Blue CMAC, CellTracker™ Orange CMRA, and LysoTracker™ Green were purchased from Fisher Scientific. 
     Cells 
     The generation and culture conditions of the stably barcoded and pooled cells (500 human cancer cell lines) are described in reference 16. The CAOV3, DAOY, HeLa, HepG2, HCC1395, HCC1143, MDA-MB-231, MCF7, SJSA-1, and SW948 cell lines were obtained from ATCC. The LOXIMVI and T47D cell lines were gifts from the Gertler Lab, and the Jurkat cell line was a gift from the Sabatini Lab. Cells were cultured at 37° C. with 5% CO 2 . Cell line-specific culture information is provided in the SLC46A3 Validation Studies section below. 
     Methods 
     The nanoparticle-specific methods described below detail conditions utilized for synthesis and characterization and have been adapted in part from references 9, 10, 11, and 16. 
     Base Liposome Synthesis 
     Cholesterol and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) were dissolved in chloroform. 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DSPG) were dissolved in a 65:35:8 mixture of chloroform, methanol and deionized water (milli-Q). A lipid mixture composed of 31 mol % DSPC, 31 mol % cholesterol, 31 mol % DSPG and 6 mol % DSPE was prepared in 50 mL round bottom flask and methanol was added dropwise until the solution cleared. The lipid solution was evaporated using a rotovap system under heat (60° C., water bath) until completely dry (&lt;15 mBarr) to make a thin lipid film. A sonicator bath was filled with milliQ water and heated until &gt;65° C. The round bottom flask containing the lipid film was partially submerged in the water bath and milliQ water was added to re-suspend the lipid film to a concentration of 2 mg lipid/mL solution. The liposome solution was sonicated for 1 minute and then removed for 1 minute. This process was repeated three times and then transferred to Avestin a liposome extruder. The extruder was connected to a Cole-Palmer Heated Recirculator Bath to maintain a temperature &gt;65° C. throughout the extruder. The liposome solution was extruded through sequentially smaller nucleopore membranes until a 50-100 nm liposome was obtained. This usually required two passes through a stack of one 400 and one 200 nm membrane followed by two passes through one 100 nm membrane and two passes through a 50 nm membrane. These liposomes were fluorescently labeled through NHS-coupling of sulfo-cyanine NHS ester dye to DSPE headgroups according to the dye manufacturer (Lumiprobe) instructions. Lipid film generation, rehydration, extrusion, and dye labeling steps were similarly applied to all liposome formulations unless noted otherwise. 
     Tangential Flow Filtration (TFF) 
     To remove excess dye, crude nanoparticle solution was connected to a Spectrum Labs system using Teflon-coated tubing. D02-E100-05-N membranes were used to purify the particles until dye was no longer seen in the permeate. This usually required 15-volume equivalent washes to be collected in the permeate. Dye levels in the permeate were monitored by running samples on a Tecan plate reader. Samples were run at flow rates of 80 mL/min with size 16 tubing. Once purified, the sample was concentrated and then recovered by reversing the direction of the peristaltic pump. To improve nanoparticle yield, 1-3 mLs of water were run backwards through the tubing to recover any remaining particles. 1×PBS was used as the exchange buffer for the first five washes followed by milliQ water for the rest of the purification steps. Following TFF, liposomes were characterized for size and zeta using dynamic light scattering (see Characterization of Nanoparticles). For LbL synthesis, TFF was used for purification between after deposition of each polyelectrolyte layer, following the above procedure. Instead of PBS, only milliQ water was passed through the TFF for LbL NP purification. 
     Synthesis of PEGylated Liposomes 
     To make the lipid stocks, cholesterol, DSPC, DSPE-PEG(2000) carboxylic acid, PEG-PE, and soy PC were dissolved in chloroform while DSPE was dissolved in a 65:35:8 mixture of chloroform, methanol and deionized water (milli-Q). For the 5% PEG formulation (LIPO-5% PEG), a lipid mixture composed of 55.67 mol % DSPC, 33.3 mol % cholesterol, 5 mol % DSPE-PEG(2000) carboxylic acid and 6 mol % DSPE was prepared in a 50 mL round bottom flask. For the 25% PEG formulation (LIPO-25% PEG), a lipid mixture composed of 35.67 mol % DSPC, 33.3 mol % cholesterol, 25 mol % DSPE-PEG(2000) carboxylic acid and 6 mol % DSPE was prepared in a 50 mL round bottom flask. For the drug-free formulation of liposomal irinotecan (LIPO-0.3% PEG*), a lipid mixture composed of 53.8 mol % DSPC, 39.9 mol % cholesterol, 0.3 mol % PEG-PE and 6 mol % DSPE was prepared in a 50 mL round bottom flask. Lastly, for the drug-free formulation of liposomal doxorubicin (LIPO-5% PEG*), a lipid mixture composed of 49 mol % soy PC, 40 mol % cholesterol, 5 mol % PEG-PE and 6 mol % DSPE was prepared in 50 mL round bottom flask. Methanol was added dropwise to all flasks until each mixture was clear. Lipid film generation, rehydration, extrusion, and dye labeling steps are described in the base liposome synthesis section. For the extrusion step, we note that the described PEGylated formulations were passed through one 400 and one 200 nm membrane followed by two passes through one 100 nm membrane. 
     PLGA Nanoparticle Synthesis 
     PLGA was dissolved at a concentration of 10 mg/mL in acetone and Cy5 free acid dye was dissolved at a concentration of 50 mg/mL in DMSO. 6 mL of milliQ water were added to a 20 mL scintillation vial and stirred gently on a plate. In a 2 mL Eppendorf tube, 2 ul of the dye was added to 1 mL of the PLGA solution, mixed and drawn into syringe with a 27-gauge needle attached. In the scintillation vial, the tip of the needle was submerged below the water line and the PLGA-Cy5 solution was slowly added to the water under constant stirring. The solution was let stir ˜3 hours to allow for solvent evaporation. An additional 2 mL milliQ water were added the solution prior to purification using tangential flow filtration (as described previously). 
     Synthesis of Layer-by-Layer Nanoparticles 
     Liposomes and PLGA nanoparticles were layered by adding an equal volume of nanoparticle solution (not exceeding 1 mg/mL) to an equal volume of polyelectrolyte solution under sonication at room temperature. The mixture was sonicated for roughly 3 seconds. The optimal weight equivalent (wt. eq.) for each layer was determined through a polyelectrolyte titration using 50 uL samples of the nanoparticle for each tested wt. eq. Each test ratio was layered as described above and then characterized. If the resulting particle had a zeta potential greater than 30 mV or less than −30 mV, and an acceptable size, it was chosen as the optimal wt. eq. for each layer. The wt. eqs. of the cationic first layer, PLR, were 0.3 for the liposome core and 0.4 for the PLGA core. For the anionic second layer, the same weight equivalents of polyelectrolyte were used for both the liposome and PLGA core. The weight equivalent of each polyelectrolyte layer are as follows: 0.65 wt. eq. PLD, 0.65 wt. eq. PLE, 1.2 wt. eq. HA, 0.65 wt. eq. dextran sulfate, 1.2 wt. eq. fucoidan, 1.2 wt. eq. alginate, 0.2 wt. eq. PAA, and 1.2 wt. eq. chondroitin sulfate. Polyelectrolyte solutions for liposome layering, except for HA and alginate, were prepared in 50 mM HEPES and 40 mM NaCl (pH 7.4) which was diluted to 25 mM HEPES and 20 mM NaCl upon 1:1 mixing with the nanoparticle substrate in water. HA and alginate stocks were prepared in 10 mM HEPES which was diluted to 5 mM HEPES upon mixing with the nanoparticle substrate in water. All polyelectrolyte solutions for PLGA nanoparticle layering were prepared in water. Layered particles were incubated at room temperature for one hour before being purified via TFF and characterized. 
     Synthesis of PEG-PLGA Nanoparticles 
     PEG-PLGA (50:50, 10k PLGA, 2k PEG) was dissolved at a concentration of 10 mg/mL in a 1:1 ratio of acetone to DMSO and cyanine5 free acid dye was dissolved at a concentration of 50 mg/mL in DMSO. 6 mL of milliQ water was added to a 20 mL scintillation vial and stirred gently on a plate. In a 2 mL Eppendorf tube, 1 μL of the dye was added to 0.5 mL of the PEG-PLGA solution, mixed and drawn into syringe with a 27-gauge needle attached. In the scintillation vial, the tip of the needle was submerged below the water line and the PEG-PLGA-cyanine5 solution was slowly added to the water under constant stirring. The solution was let stir ˜3 hours to allow for solvent evaporation. An additional 2 mL milliQ water were added the solution prior to purification via TFF and characterization. 
     PEGylation of Carboxylated Polystyrene Nanoparticles 
     20, 100 and 200 nm yellow green carboxylated fluospheres were prepared at stocks of 2% solids and 40 nm yellow green carboxylated fluospheres were prepared at a stock of 5% solids. A 5 mg/mL stock of 3k PEG-NH 3 Cl was prepared in DPBS and a 15 mg/mL stock of EDC was prepared in PBS. For the 20, 100 and 200 nm fluospheres, 200 μLs of 3k PEG-NH 3 Cl and 100 μLs of each fluospheres were combined and mixed in separate 1.5 mL Eppendorf tubes. For the 40 nm fluosphere, 200 uLs of 3k PEG-NH 3 Cl and 40 uLs of fluospheres were combined and mixed in a 1.5 mL Eppendorf tube. To each Eppendorf tube, 200 μL of the EDC solution was added. All reactions were carried out a room temperature and protected from light for 6-8 hours while mixing. 
     Fluorescently Tagging Antibodies 
     The cetuximab antibody was prepared in 0.1M sodium bicarbonate (pH 8.2) at a concentration of 0.5 mg/mL and the isotype IgG antibody was prepared in water at 2 mg/mL. SulfoCy5 NHS ester dye was prepared in DMSO at a concentration of 50 mg/mL. 200 μL of the cetuximab antibody was added to a protein lobind tube. In a separate protein lobind tube, 50 μL of the IgG antibody was added with 150 μL of 0.1M sodium bicarbonate (pH 8.4). To each solution, 1 μL of sulfoCyS NHS ester dye was added. Both reactions were carried out a room temperature and protected from light for 6-8 hours while mixing. To purify the antibodies, a 3k MWCO spin column was used. Each antibody was washed 15 times to purify. 
     Conjugation of Antibodies to Nanoparticles 
     EDC and sulfoNHS stocks were prepared at 10 mg/mL in water. Isotype IgG and cetuximab antibodies were prepared at 0.2 mg/mL in PBS. 25% PEG liposomes (LIPO-25% PEG) were prepared at 1 mg/mL in water. 1 mL of nanoparticle was added to two separate protein lobind tubes. To each tube, 8 uL of EDC and 16 uL of sulfoNHS was added. Each tube was mixed at room temperature and protected from light for 30 minutes. 0.5 mL of isotype IgG was added to one lobind tube and 0.5 mL of cetuximab was added to the other lobind tube. Each reaction was mixed at room temperature and protected from light for 1 hour. After an hour, tangential flow filtration was used for purification and nanoparticles were characterized via DLS. 
     Synthesis of Solid Lipid Nanoparticles (LNPs) 
     GFP mRNA was dissolved in sodium acetate buffer (25 mM, pH 2.5) in a glass vial equipped with a stir bar and lipids (cationic lipid: 5 mg/mL, PEG lipid: 1 mg/mL, phospholipids: 5 mg/mL, cholesterol: 4 mg/mL) were separately dissolved in ethanol at a constant molar ratio. See table 5 for specific ratios. The mRNA solution was stirred at 700 rpm and the lipid mixture was added under stirring. After stirring for 10 seconds, the solution was let rest for 5 minutes. After this, the solution was diluted 1:1 with RNAase-free water. Resulting LNPs were purified via ultracentrifugation and stored at 4° C. mRNA encapsulation was quantified using the commercially available RiboGreen assay. 
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                 Characterization of LNPs 1 and 2 detailed in table 5. 
               
            
           
           
               
               
               
               
               
            
               
                   
                   
                   
                   
                 mRNA 
               
               
                   
                 Z-average 
                   
                 Zeta Potential 
                 encapsulation 
               
               
                   
                 (nm) 
                 PDI 
                 (mv) 
                 (%) 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
            
               
                 LNP1 
                 100.5 ± 3.0 
                 0.125 ± 0.054 
                 18.2 + 2.9 
                 91 
               
               
                 LNP2 
                 112.8 ± 1.0 
                 0.216 ± 0.027 
                 35.2 + 1.7 
                 92 
               
               
                   
               
            
           
         
       
     
     Characterization of Nanoparticles 
     Nanoparticle hydrodynamic size and polydispersity were measured using dynamic light scattering (Malvern ZS90 Particle Analyzer). Zeta measurements were also acquired with the Malvern ZS90 using laser doppler electrophoresis. Nanoparticle solutions were diluted in milliQ water in polystyrene, semi-micro cuvettes for size measurements and DTS1070 folded capillary cuvettes for zeta measurements. For LIPO-5% PEG, LIPO-25% PEG, LIPO-5% PEG*, LIPO-EGFR and LIPO-IgG, the hydrodynamic size for each nanoparticle was measured using high throughput dynamic light scattering (Wyatt Dyna Pro Plate Reader) with samples diluted in milliQ water and tested in a black, glass bottom 384 well plate. 
     Pooled PRISM Cell Dosing with NPs and Preparation for Flow Cytometry 
     Cells were seeded at 200,000 cells/well in 0.5 mL RPMI-1640 media supplemented with 10% FBS in a 12-well plate. Cells were allowed to grow for 24 hours prior to treatment with nanoparticles. Prior to dosing, all PLGA nanoparticle formulations were normalized to a concentration of 50 μg/mL and all other nanoparticle formulations were normalized to a concentration of 100 μg/mL. Cells were dosed with 50 μL of normalized PLGA nanoparticles and 25 μL of normalized nanoparticles for all other formulations. Cells and nanoparticles were incubated for either 4 or 24 hours at 37° C. and 5% CO 2 . 
     After incubation, cells were washed once with 500 μL of warm PBS and dissociated with 150 μL 0.25% Trypsin-EDTA. After 5 minutes at 37° C., the trypsin was quenched with 200 μL of media and the cells were triturated vigorously to ensure that all cells had been dissociated from the plate. Cells were then transferred to a fluorescence-activated cell sorting (FACS) tube through a cell strainer cap and placed on ice until sorted. 
     Pooled PRISM Cell Dosing with Antibodies 
     10 wells of cells were washed twice with 200 μL of room temperature PBS and dissociated with 200 μL of accutase by incubating at 37° C. for 5 mins. After incubation, 300 μL of cold FACS buffer (PBS+2% FBS) was added to each well and the cells were triturated. Each well was transferred and combined in a 15 mL falcon tube and spun at 1000 rpm for 5 minutes at 4° C. After spinning, the supernatant was removed and the cells were counted and resuspended in FACS buffer at a concentration of 1e6 cells/mL. 200 μLs of the cell suspension was transferred to 12 separate FACS tubes. To three of the tubes, nothing was added to remain as an untreated control. To three tubes, 15 μL of 0.1 mg/mL Cy5-cetuximab was added. To three tubes, 15 μL of 0.1 mg/mL Cy5-IgG was added. To the final three tubes, 5 μL of EGFR-AF488 (used at undiluted stock concentration provided by manufacturer) were added. All tubes were vortexed gently and incubated in the dark at 4° C. for one hour. After an hour, 200 μL of cold FACS buffer was added to each tube, the cells were triturated and then spun at 1000 rpm for 5 minutes at 4° C. After centrifugation, the supernatant was removed and the cells were resuspended in 300 μL of cold FACS buffer. The cells were stored on ice until flow sorting. 
     Preparation of Untreated and Sorting Control Samples 
     Cells were washed once with warm PBS. For cells that were lysed in well, 150 μL of lysis buffer was added to each well and cells were incubated for 5 minutes at 37° C. After incubation, 100 μL of PBS was added and the lysed cells were triturated and transferred to an Eppendorf tube. For trypsinized cells, after a PBS wash, 150 μL 0.25% Trypsin-EDTA was added to the wells and incubated for 5 minutes at 37° C. To quench the trypsin, 200 μL of media was added to the well and the cells were triturated and transferred to either a FACS tube (for sorted control) or Eppendorf tube (for unsorted control). The unsorted control cells were pelleted by centrifuging at 1000 rpm for 5 minutes and resuspended directly into 150 μL of lysis buffer. 
     Flow Cytometry and FACS Information 
     For FACS, samples were sorted using a BD Cell Sorter (BD Biosciences). Samples dosed with Cy5 nanoparticles or Cy5 antibodies were sorted on the APC channel (ex. 640, filters 660/20). Samples dosed with yellow green fluospheres or AF-488 antibodies were sorted on the GFP channel (ex. 488, filters 530/30). 
     For all flow analysis in validation studies, samples were analyzed using a BD Flow Cytometer with high throughput sampler (BD Biosciences). Samples dosed with Cy5 nanoparticles were analyzed on the APC channel (ex. 640, filters 670/30). Samples dosed with yellow green fluospheres were analyzed on the GFP channel (ex. 488, filters 515/20). Data was analyzed using FlowJo™ (version 10), and cells were gated for single cells based on an untreated, parental cell line for each condition using the side scatter and forward scatter plots; singlet gates were applied to all samples of the same parental cell line. Analysis of NP intensity was based on a single color (APC or GFP, as above) without compensation. 
     PRISMseq 
     Samples lysed in DNA Lysis Buffer (20 mM Tris-HCl (pH 8.4), 50 mM KCl, 0.45% NP-40, 0.45% Tween-20, 10% Proteinase K) were denatured at 95° C. and amplified with a 2×KAPA polymerase master mix. Custom primers (IDT) allowed samples to be dual-indexed for multiplexed Illumina sequencing by directly adding Illumina flow-cell binding sequences to the amplicon: 
                            forward primer:           (SEQ ID NO: 3)           5′AATGATACGGCGACCACCGAGATCTACANNNNNNNN                       AAGGTGCTTCTCGATCTGCAT                       reverse primer:           (SEQ ID NO: 4)           5′CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTGA                       CTGGAGTTCAGACGTGTGCT,            
where N represents the indexing nucleotides. Resulting products were quality control checked for single-band amplification using gel electrophoresis and then pooled and purified for sequencing using the Zymo DNA Clean &amp; Concentrator kit. After pooling, the PCR product was quantified using a Fluorometer. Samples were sequenced using Illumina technology. Samples were loaded onto the flow cell at a final concentration of 10 pM with a 20% PhiX spike-in due to low diversity. Sequencing was run for 50 cycles, single-read.
 
     SLC46A3 Validation Studies 
     Non Pooled Screening 
     HCC1143 (RPMI-1640), HCC1395 (RPMI-1640), HeLa (RPMI-1640), SW948 (RPMI-1640), LOXIMVI (RPMI-1640), SJSA-1 (RPMI-1640), MCF7 (Eagle&#39;s Minimum Essential Medium, EMEM), DAOY (EMEM), MDA-MB-231 (Dulbecco&#39;s Modified Eagle&#39;s Medium, DMEM), CAOV3 (DMEM), T47D (RPMI-1640), and HepG2 (DMEM) cells were seeded individually at 10,000 cells/well in 1004 of media, supplemented with 10% FBS and 1× Penicillin-Streptomycin. Base media are provided in parentheses following cell line names. Cells were allowed to grow overnight prior to treatment with nanoparticles. Prior to dosing, all nanoparticle formulations were normalized to a concentration of 50 μg/mL. Cells were dosed with 104 of normalized nanoparticles. Cells and nanoparticles were incubated for either 4 or 24 hours at 37° C. and 5% CO2. 
     After incubation, cells were washed once with 1004 of warm PBS and dissociated with 20 μL 0.25% Trypsin-EDTA. After 5 minutes at 37° C., the trypsin was quenched with 1804 of media and the cells were triturated vigorously to ensure that all cells had been dissociated from the plate. Cells were placed on ice until analyzed using high throughput sampler. 
     SLC46A3 Overexpression: Viral Transfection of LOXIMVI Cells 
     Lentiviral vectors were purchased from the Broad Institute&#39;s Genetic Perturbation Platform (GPP), specifically ccsbBroad304_09945 (SLC46A3) and ccsbBroad304_99991 (Luciferase, vector control). 
     LOXIMVI cells were grown and passaged in RPMI-1640 supplemented with 10% FBS and 1× Pen/Strep until ready for infection. LOXIMVI cells were trypsinized, counted and resuspended to a concentration of 1.36×10 6  cells/mL. A solution of 2× polybrene was added to the cell suspension such that the final concentration of polybrene was 8 μg/mL. Cells were seeded into two six-well plates at 750,000 cells/well. Lentiviral vectors were separately added to plates at six different doses: 0, 25, 50, 100, 200, and 400 μLs. After, 1 mL of media was added to each well and the cells were incubated overnight at 37° C. and 5% CO 2  and media changed at 17 hours post-seeding. At 48 hours after seeding, the cells were re-seeded at 375,000 cells/well in 2 mLs of blasticidin containing media (final blasticidin concentration was 1 μg/mL). The selection progress was monitored via flow cytometry ( FIG. 8 ). 
     SLC46A3 Knock-Out Via CRISPR-Cas9 in T47D Cells 
     SLC46A3 knock-out T47D cell lines were generated by infection with lentiCRISPRv2-Opti (Addgene #163126) vectors encoding Cas9 and single guide RNAs (sgRNAs). 51  The following oligonucleotides were used for sgRNA cloning and include cloning overhangs for ligation after BsmBI digest of lentiCRISPRv2-Opti vector: 
     
       
         
           
               
               
            
               
                   
                 sgGFP_F: 
               
               
                   
                 (SEQ ID NO: 5) 
               
               
                   
                 caccGGGCGAGGAGCTGTTCACCG 
               
               
                   
                   
               
               
                   
                 sgGFP_R: 
               
               
                   
                 (SEQ ID NO: 6) 
               
               
                   
                 aaacCGGTGAACAGCTCCTCGCCC 
               
               
                   
                   
               
               
                   
                 sgSLC46A3_F: 
               
               
                   
                 (SEQ ID NO: 7) 
               
               
                   
                 caccgAAAGCAAGCTCCCCAAAATG 
               
               
                   
                   
               
               
                   
                 sgSLC46A3_R: 
               
               
                   
                 (SEQ ID NO: 8) 
               
               
                   
                 aaacCATTTTGGGGAGCTTGCTTTc 
               
            
           
         
       
     
     Clonal knock-out cell lines were isolated through fluorescence-activated cell sorting, and biallelic frame-shifts were confirmed by deep-sequencing (allele 1: −32 bp frameshift 501 reads; allele 2: −10 bp frameshift; 477 reads). The T47D SLC46A3 knock-out line described has the mutant alleles c.442_453del and c.440_449del. 
     Quantification of SLC46A3 protein expression via western blot was not possible due to the lack of commercially available antibodies with proper specificity. In addition to our own experimental conclusions, this point has also been referenced in the literature. 48    
     SLC46A3 Knockdown Via siRNA in T47D Cells 
     T47D cells were plated in a 96 well plate at 8,000 cells per well and let grow for 24 hours. Then, siRNA (Silencer Select s49280) against SLC46A3 and a non-targeting, scramble control (siScramble) were dosed using a commercially available transfection kit and protocol. After 24 hours, Cy5 labeled LIPO-0.3% PEG was added at the same concentration and amount noted above and incubated for an additional 24 hours prior to flow cytometry assessment of NP-cell association. 
     For PCR profiling, T47D cells were plated in a 6 well plate at 400,000 cells per well and let grow for 24 hours. Then, Then, siRNA (Silencer Select s49280) against SLC46A3 and a non-targeting, scramble control (siScramble) were dosed using a commercially available transfection kit and protocol. Knockdown was assessed both 24 and 48 hours post transfection via PCR. 
     Quantitative Real-Time PCR for SLC46A3 Transcript Levels 
     Total RNA was prepared from the indicated cell lines using a kit from Qiagen. cDNA synthesis was performed using the Invitrogen SuperScript™ VILO system (ThermoFisher Scientific) according to the manufacturer&#39;s instructions prior to quantitative real-time PCR with the Applied Biosystems PowerUP™ SYBR Green master mix (ThermoFisher Scientific) using an Applied Biosystems QuantStudio™ 6 instrument in fast mode. Quantitation of transcript abundance was calculated from standard curves and normalized to 18S rRNA. The following oligonucleotides were used for real-time PCR: 
     
       
         
           
               
               
            
               
                   
                 SLC46A3_F: 
               
               
                   
                 (SEQ ID NO: 9) 
               
               
                   
                 tgccattctctgttctacgg 
               
               
                   
                   
               
               
                   
                 SLC46A3_R: 
               
               
                   
                 (SEQ ID NO: 10) 
               
               
                   
                 tgcagtgactcctccaagtg 
               
               
                   
                   
               
               
                   
                 185 rRNA_F: 
               
               
                   
                 (SEQ ID NO: 11) 
               
               
                   
                 agacaaatcgctccaccaac 
               
               
                   
                   
               
               
                   
                 18S rRNA_R: 
               
               
                   
                 (SEQ ID NO: 12 
               
               
                   
                 cctgcggcttaatttgactc) 
               
            
           
         
       
     
     Imaging Cytometry Sample Preparation 
     Engineered T47D and LOXIMVI cells were plated in T25 flasks in 5 mL of media at the following densities: 2.3-2.6×10 6  cells/flask for LOXIMVI-vector control, LOXIMVI-SLC46A3 OE, and T47D-vector control cells; 3.8×10 6  cells/flask for T47D-SLC46A3 knockout cells. Cells were allowed to adhere for 24 h (37° C., 5% CO 2 ) prior to treatment with 250 μL NP solutions, ranging from 0.05-0.1 mg/mL core concentration, for 24 h. 
     For CellTracker™/LysoTracker™ staining, the following staining solutions were prepared: 50 nM LysoTracker™ Green and/or 50 μM CellTracker™ Orange CMRA in serum-free RPMI-1640. CellTracker™ and LysoTracker™ concentrations were selected based on manufacturer recommendations as well as literature protocol 52 . 
     Cells were trypsinized and transferred to 15 mL falcon tubes prior to washing 2× with warmed PBS. Between washes, cells were pelleted at 300 rcf for 5 min. For CellTracker” and LysoTracker™ staining, cells were re-suspended in 0.5 mL respective staining solution, and incubated in the dark at 37° C. for 60 min. Cells were then pelleted and washed 2× with warmed PBS. 
     For fixation, cell pellets were re-suspended in 2% formaldehyde in PBS, incubated on ice for 20 min, then washed 2× with PBS. Cell pellets were then re-suspended in Hoechst-3342 (1 μg/mL in PBS) for 2 min prior to washing 2× with PBS. Cells were re-suspended and stored in 2% FBS in PBS overnight prior to running samples on ImageStream. 
     Samples were run on an ImageStreamX™ Mark II(Luminex). Single color controls were prepared using the above protocol for compensation. For analysis, only the Cy5 (NP) and brightfield channels were used. 
     Imaging Cytometry Analysis Workflow 
     Data analysis was carried out using AMNIS IDEAS™ software (version 6.2). First, singlet cells were gated based upon scatter plots using brightfield images (Ch01), with aspect ratio intensity on the y-axis and cell area on the x-axis; the same gate was used for all samples. Using the built-in software functionality, the brightfield mask with a 5% erosion was applied to all singlet cells, and a cellular distribution score was generated using the built-in ‘Internalization’ function in the IDEAS software. Raw data was exported from IDEAS as ‘.fcs’ files, and data was FlowJo™ software was used to visualize the data and compute metrics such as median intensity and median cellular distribution scores. 
     Deconvolution Optical Microscopy 
     Chambered cover glass was coated with rat tail collagen (Coming, 3004 of 50 Kg/mL in 0.02N acetic acid). After 5 minutes, the wells were washed with room temperature PBS and allowed to dry in a sterile environment. Wells were stored at 4° C. up to one week prior to seeding cells in 3004 media at the following densities: 5,000 cells/well for T47D-vector control cells, LOXIMVI-vector control and SLC46A3 OE cells; 5,500 cells/well for T47D-SLC46A3 KO cells. The cells were allowed to adhere for 24 h (37° C., 5% CO 2 ) prior to treatment with 154 of a 0.1 mg/mL NP solution (Cy5 channel) for either 4 or 24 h. Then, cells were washed 3× with warm PBS before adding LysoTracker™ Green (130 nM final concentration)+CellTracker™ Blue CMAC (13 μM final concentration) solution, which was prepared right before use in phenol red-free RPMI 1640. Cells were incubated in the dark at 37° C., 5% CO 2  for 45 min prior to aspirating dye solution, washing 3× with warm PBS, and adding 3004 phenol red-free RPMI 1640 to each well. The cells were imaged with the Applied Precision DeltaVision™ Ultimate Focus Microscope with TIRF Module (Inverted Olympus X71 microscope) equipped with 405, 488, 512, and 568 nm lasers. Images were acquired with a either a 60× (with enhanced magnification) or 100× objective. All images were acquired with OMX softWoRx™ software (Applied Precison/GE). Image LUTs were linearly adjusted to improve contrast using FIJI. Z slices were merged into Z projections as shown in  FIGS. 3G-H  and  8 . For CellTracker™ signal, a single (bottom most) slice was interleaved with the Z projection of the NP and LysoTracker™ signal. 
     Animal Studies 
     All animal experiments were approved by the Massachusetts Institute of Technology Committee on Animal Care (CAC) and were conducted under the oversight of the Division of Comparative Medicine (DCM). Flank tumors of LOXIMVI-vector control and LOXIMVI-SLC46A3 OE cells were established with a subcutaneous injection of 0.5-1.0×10 6  cells as a 1:1 mixture with MatriGel™ (Corning) and PBS to the right flank of NCr nude mice. 
     Nanoparticle Formulation 
     Cy5 labeled NPs (1 mg/mL, LIPO-0.3% PEG*) were formulated in 5% dextrose (sterilized by filtering through a 0.2 μM filter). 
     Intratumoral Injection Studies 
     For intratumoral (IT) studies, within genders, mice with established flank tumors were randomly assigned to either the 4 or 24 h dosing cohort (n=10; for 4 hour time point n=5 female+5 male mice, for 24 hour time point, n=6 female+4 male mice/cohort). Four or 24 hours after injection, mice were imaged using the In Vivo Imaging System (IVIS) Spectrum whole animal imaging device (PerkinElmer) using ex=640/em=700 nm to capture Cy5 signal. Immediately following imaging, mice were humanely euthanized and tumors were excised and imaged again via IVIS. Tumors were then placed into pre-weighed tubes containing 1 mL PBS. Tumors were weighed and their weights recorded for normalization of tumor fluorescence by tumor mass. 
     Tumor tissue was embedded in OCT™ compound (Tissue-Tek) and frozen over dry ice prior to sectioning. Sectioning and hematoxylin and eosin (H&amp;E) staining was performed by Koch Institute&#39;s histology core facility. 
     To confirm animal gender did not confound our findings, using data obtained from the IT study, we compared the total radiant efficiency divided by tumor mass (mg) of male and female mice at both the 4 and 24 h time points, and we did not find a statistically significant difference in NP tumor accumulation (p&gt;0.05). 
     Intravenous Injection Studies 
     For intravenous (IV) studies, n=10 for the SLC46A3 overexpressing group (n=5 female+5 male mice) and n=9 for the vector control group (n=5 female+5 male mice). Nanoparticles were administered to mice using tail vein injections (3 total, spaced 24 hour apart). Four hours after the third and final injection, mice were humanely euthanized and tumors were excised and imaged using the In Vivo Imaging System Lumina whole animal imaging device (PerkinElmer) to capture Cy5 signal (ex=620/em=670 nm). Tumors were then placed into pre-weighed tubes containing 1 mL PBS. Tumors were weighed and their weights recorded for normalization of tumor fluorescence by tumor mass. 
     Statistical Analysis 
     Methods pertaining to nanoPRISM analysis are detailed in Supplementary Text, below. All statistical analysis for non-pooled validation studies was performed using GraphPad PRISM 9. For single comparisons (non-parametric), the Mann-Whitney test was used. For multiple comparison testing, the Kruskall-Wallis test was used to compare treatment groups to the parental control. 
     Supplementary Text 
     nanoPRISM Probabilistic Model Development 
     In the statistical analysis of the sequencing data, a simple probabilistic model is employed to infer each cell&#39;s probability from a given cell line to fall into the predefined bins after treating with a given NP formulation In particular, for each NP treatment, the observed count for cell line. and bin j and technical replicate k is denoted with x i,j,k , and standard Poisson model for sequencing noise is assumed, i.e. x i,j,k ˜Pois(μ i,j,k ). 
     Furthermore, the expected value of this random variable, μ i,j,k , is factored into three operational quantities μ i,j,k =λ j,k S i P i,j , where λ j,k  is a sample-specific scaling factor to take into the sequencing and PCR efficiency into account. S i  is the initial abundance of line before the treatment, and P i,j  is the probability of each cell to fall into bin j. 
     In this formulation, we denote the control samples (not sorted into the bins) with a dummy binj=0 and P i,0 =1 for all i, and maximize the likelihood function 
     
       
         
           
             L 
             = 
             
               
                 
                   ∑ 
                   
                     i 
                     , 
                     j 
                     , 
                     k 
                   
                 
                 
                   
                     x 
                     
                       i 
                       , 
                       j 
                       , 
                       k 
                     
                   
                   ⁢ 
                   
                     log 
                     ⁡ 
                     ( 
                     
                       
                         S 
                         i 
                       
                       ⁢ 
                       
                         P 
                         
                           i 
                           , 
                           j 
                         
                       
                       ⁢ 
                       
                         λ 
                         
                           j 
                           , 
                           k 
                         
                       
                     
                     ) 
                   
                 
               
               - 
               
                 
                   S 
                   i 
                 
                 ⁢ 
                 
                   P 
                   
                     i 
                     , 
                     j 
                   
                 
                 ⁢ 
                 
                   λ 
                   
                     j 
                     , 
                     k 
                   
                 
               
               - 
               
                 log 
                 ⁡ 
                 ( 
                 
                   
                     x 
                     
                       i 
                       , 
                       j 
                       , 
                       k 
                     
                   
                   ! 
                 
                 ) 
               
             
           
         
       
     
     subject to the constraints P i,A +P i,B +P i,C +P i,D =1, S i &gt;0, λ j,k &gt;0, P i,k ≥0, for all i, j, k, using a standard projected gradient descent algorithm to infer the binning probabilities P i,k  independently for each biological sample and their concordance across replicates are used as a QC check. The R scripts used to process the data and infer the binning probabilities are available upon request. 
     Univariate Analysis Description 
     For each given WA profile and each dataset in the cancer cell line encyclopedia (CCLE), we regressed the WA profile of the NP formulation on each column of the feature dataset and calculated the regression coefficient along with its corresponding standard error under the homogeneity assumption. Next, we applied the adaptive shrinkage method 53  to obtain moderated effect sizes, standard deviations and corresponding q-values. In the figures, the ratio of the posterior effect sizes and the standard deviations are presented as z-scores. This analysis was conducted in R 54  and figures were produced using the package ggplot2 55 . 
     Random Forest Description 
     For the multivariate biomarker analysis, the weighted average of the binning probabilities scores, W&#39;s, are used as the response variable and standard random forest regression models (RF) fitted proceeding a correlation-based feature selection. In particular, we fit two RF models for each NP formulation where the first one, CCLE model, uses a concatenation of the core cell line characteristics (mRNA expression, mutation status, copy number changes, and lineage annotations), while the second one, ALL, includes more features (proteomics, CRISPR knock-outs, micro RNA, metabolomics) by limiting the analysis on the overlapping cell lines across all the datasets. For each model, 10-fold cross-validation is employed while in each fold an RF model fit after choosing the most correlated 500 features to the response variable). The cross-validated predictions then used to calculate Pearson scores (the correlation between the observed and predicted responses), and R 2  values to assess the model performance. As the final step, these values are reported along with the default feature importances. 
     Principal Component Analysis and K-Means Clustering 
     Principal component analysis (PCA) was performed using the weighted average of each nanoparticle-cell line pair from the by collapsing data by nanoparticle or cell-line. K-means clustering was performed on a subset of biomarkers generated by RF method that met the following criteria: CCLE features including gene expression, gene copy number, or protein abundance; univariate analysis z-score greater than 0. The Pearson correlation for biomarkers was then input for k-means clustering to generate 5 clusters. These analyses were conducted in R using ggfortify 56,57  to perform PCA or k-means clustering and figures were produced using the package ggplot2 55 .